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ABSTRACT
More than a decade into the development o f gold nanoparticles, with multiple 
clinical trials underway, ongoing pre-clinical research continues towards better 
understanding in vivo interactions. The goal is treatment optimization through improved 
best practices. In an effort to collect information for healthcare providers enabling 
informed decisions in a relevant time frame, instrumentation for real-time plasma 
concentration (multi-wavelength photoplethysmography) and protocols for rapid 
elemental analysis (energy dispersive X-Ray fluorescence) o f biopsied tumor tissue have 
been developed in a murine model. An initial analysis, designed to demonstrate the 
robust nature and utility o f the techniques, revealed that area under the bioavailability 
curve (AUC) alone does not currently inform tumor accumulation with a high degree of 
accuracy (R2=0.56), marginally better than injected dose (R2=0.46). This finding 
suggests that the control o f additional experimental and physiological variables (chosen 
through modeling efforts) may yield more predictable tumor accumulation. Subject core 
temperature, blood pressure, and tumor perfusion are evaluated relative to particle uptake 
in a murine tumor model. New research efforts are also focused on adjuvant therapies 
that are employed to modify circulation parameters, including the AUC, o f nanorods and 
gold nanoshells. Preliminary studies demonstrated a greater than 300% increase in 
average AUC using a reticuloendothelial blockade agent versus control groups. Given a 
better understanding o f the relative importance o f the physiological factors that influence
rates o f tumor accumulation, a set o f experimental best practices is presented. This 
dissertation outlines the experimental protocols conducted, and discusses the real-world 
needs discovered and how these needs became specifications o f developed protocols.
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CHAPTER 1
INTRODUCTION
1.1 Introduction to Cancer
Cancer is a blanket term used for several different diseases and types o f conditions. 
These conditions all demonstrate an uncontrolled growth and potential spread of mutated 
cells. Cancer is observed across all genders, races, and ethnicities. Approximately 
1,660,290 new cancer diagnoses and approximately 580,350 deaths from cancer are 
expected in the United States in 2013. This disease also carries a cost (in 2008) o f $77.4 
billion in medical costs and $124 billion in lost productivity. [1] Estimations based on 
current cancer research and clinical trials suggest that by the year 2022 the number of 
cancer survivors will increase from 13.7 million Americans in 2012 to around 18 million 
Americans. [2]
The nature o f most tumors suggest that there is a problem in the regulations o f tumor- 
suppressor genes, oncogenes and/or the apoptosis regulators. It is believed that it takes 
multiple mutations o f the oncogenes and tumor-suppressor genes to result in malignant 
tumor. [3] Cancer cells demonstrate changes that lead to a defect in the normal regulatory 
systems o f cell proliferation and homeostasis. [4] These problems with the cell 
proliferation and homeostasis are connected with a problem with the two pathways of 
apoptosis (Stress pathway, and death receptor pathway). [3]
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2Solid tumors account for approximately 85% of cancers, and are the subject o f a 
large international research effort. [5] The successful outcome of tumor treatments often 
depends on physicians’ experience and available techniques. [6], [7] Survival rates have 
improved over the past few decades with a one-year’s survival rate going from 69.9% in 
1975 to 81.8% in 2008, and a 10 year survival rate going from 41.9% in 1975 to 60.6% in 
1999. [1], [2], [8] Tumors that are surgically accessible are removed. If surgical removal 
is not feasible, which can be the case for tumors that lie near sensitive tissues, such as 
head, neck, and brain, or those that have metastasized, often fall within the domain of 
radiation or chemotherapy. [9] Chemotherapy involves injecting an inherently toxic 
substance [10] and relies on the high metabolic activity o f malignant cells to quickly 
absorb the chemotherapeutic agent. However, the uptake and retention o f traditional 
chemotherapeutic small/macro-molecules can be hindered by abnormal blood and 
interstitial fluid pressures (IFP) in the tumors [11] and thus, even less systemically toxic 
agents (such as Herceptin), developed in recent years [12], can cause significant side 
effects.
Identified at least thirty years ago, the anatomical and physiological 
characteristics o f tumors underwent much study in the 1980s [13], [14] and 1990s [15], 
but since these characteristics vary with tumor size, type, and location [16], [17], 
quantifying usable metrics to inform drug and nanoparticle design have been elusive. 
Although early empirical studies have identified the particle’s size that provides 
substantial improvement over the weak uptake observed with macromolecules in some 
tumors [18], these studies are not general in form and do not necessarily apply to other 
particles or conditions.
3Sensing and imaging technologies that are capable o f quantitatively characterizing 
the scale o f nanoparticles have enabled the development o f the first round o f nanomedical 
technologies at an experimental or prototype level. An examination o f the literature and 
interaction with various companies currently involved in clinical trials suggest that the 
variability in the quality control o f the manufacture, storage, and experimental protocols 
make comparisons difficult. [19]
Some of the nanomaterials currently found in the market for cancer therapies are 
nanocarrier-based drugs. A few examples are Zinostatin, Stimalmer, Oncaspar, Ontak, 
Zevalin, Bexxar, Myocet, and Abraxane. These carriers include protein conjugates, 
immunoconjugates, and liposomes. [20] Additional types of nanomaterials, such as 
Auroshells and Combidex, are currently undergoing clinical trials. These particles are 
gold nanoshells and iron oxide nanoparticles, respectively. [21] Gold nanoshells and 
nanorods have unique optical properties that allow for non-invasive, real-time monitoring 
o f nanoparticle concentration in the blood. [22]—[24] However, whatever type o f 
nanoparticle is chosen, o f key importance in nanoparticle-based cancer treatment is the 
exploitation o f the natural differences between cancerous and healthy tissue for the 
selective delivery to tumor cells in order to reduce damage to healthy cells. Indeed, some 
tumors present a unique physiology that distinguishes them from healthy tissue; in 
particular, they are characterized by an abnormal vasculature and the lack o f functioning 
lymphatic vessels. [14] Studies have demonstrated that the vasculature o f some tumors is 
quantifiably different from normal tissue in the lack o f a complete basement membrane, 
abnormally large interendothelial junctions, permeability, and size [5], [14] and these 
differences are commonly exploited for passive delivery via the enhanced permeability
4and retention effect (EPR). For example, the average pore cutoff size in tumors is much 
larger (380-780 nm dia. [15]) than for normal blood vessels (10-20 nm dia. [25]) and 
thus larger nanoparticles will be selectively absorbed in tumors over healthy tissue. 
However, some other characteristics o f tumor tissue, such as higher 1FP than normal 
tissue [26], lead to a less efficient delivery. Thus, a careful study of all these factors is 
important in order to take better advantage of those properties resulting in an increased 
delivery while minimizing the effect of those that would make the delivery less effective.
1.2 Nanoparticles in Development for Cancer Therapies
Several types of nanomaterials are currently under investigation in multiple stages o f 
preclinical and clinical trials for use in cancer therapies. Some of these nanomaterials 
include liposomes and micelles (Doxil/Caelyx), polymer (Oncaspar), iron oxide 
(NanoTherm), and gold nanoshells (Auroshell). [21] The nanomaterials are used due to 
the ability to engineer specific characteristics to target tumors. Nanomaterials either 
actively (by attaching molecules that bind to antigens or receptors on target cells) or 
passively (by exploiting EPR) accumulate in tumor tissue. [20]
The EPR effect is a commonly found defect in the vessel walls of tumors. As tumors 
rapidly grow the need for nutrients is significant, as a result healthy vasculature is unable 
to keep up with the constant demand for more nutrients. The expansion o f the vasculature 
toward the tumor is supported by vascular endothelial growth factor and basic fibroblast 
growth factor. An imbalance in the pro- and anti- growth factors leads to poorly regulated 
expansion o f the vasculature. This lack o f oversight leads to poorly formed vessels and 
defective basement architecture allowing larger particles and molecules to escape the
5vasculature in these areas. These larger particles are not able to escape the well-formed 
(healthy or non-tumorous) vasculature. [27]
1.2.1 Active vs. Passive Tumor Targeting
1.2.1.1 Passive Targeting
Passive tumor targeting involves the EPR effect. This effect in combination with the
poor lymphatic drainage creates an environment where specifically sized particles can 
preferentially accumulate, compared to normal tissue. This specific set o f conditions is a 
result o f the rapid angiogenesis necessary for the rapid and unchecked growth o f tumor 
tissue. Research suggests that taking advantage o f these factors alone particles up to 
approximately 400 nm are able to extravagate, but particles under 200 nm are most 
effective. [20] A model suggested that the pore size is more important than the particle 
size for effective extravasation. [28] Pore size (a factor in perfusion) can be modified by 
several methods including hyperthermia. [28], [29] Once in the target tissue the particle 
would complete an action it is designed to do, such as heat when energy (light or 
magnetic) is applied or release a chemotherapeutic agent.
1.2.1.2 Active Tarzetins
The purpose o f active targeting is to avoid problems, such as poor perfusion, by 
designing particles to bind to specific cells after extravasation from the vasculature. This 
is typically done by attaching targeting agents (generally classified as proteins, nucleic 
acids, or receptor ligands) to the surface o f the particle. These agents must be highly 
specific to the target tissue type, or the particle would complete its action on an undesired 
tissue. Some particles have such a high binding affinity that they have lost some 
penetration depth. [20] Active targeting techniques using surface modifications to gold
6nanorods have demonstrated a small improvement compared to passive accumulated 
control groups. [30] This result brings up questions regarding the utility o f active 
targeting and the importance o f perfusion and injection route (regardless o f targeting) in 
accumulation.
1.2.2 Types o f Nanoparticles
1.2.2.1 Liposomes
Liposomes are spherical and made o f a lipid bilayer, creating a core area potentially 
used for encapsulation o f drugs. This method is advantageous due to the ability o f the 
liposomes to preferentially accumulate in tumors due to the EPR effect. The preferential 
accumulation in tumors allows the chemotherapeutic agent in the liposome to be given in 
lower doses, and be less systemically toxic while retaining the desired toxicity and 
concentration in the target tumor. Liposomes also allow for the manipulation of 
properties such as size, drug release rate, bioavailability, and dosing schedule can 
increase efficacy while lowering damage to other tissues. The United States FDA first 
approved this type o f therapeutic agent in 1990 as DOXIL (liposomal doxorubicin). [31 ]
1.2.2.2 Hvdroeel
Hydrogels are network o f cross-linked polymer chains that are hydrophilic and 
commonly used as tissue scaffolds. Several studies have been and are being conducted 
using cross-linkers that will degrade under specific conditions, usually to release an 
encapsulated drug. Tauro and colleagues have demonstrated potential use of 
poiy(ethylene glycol) diacrylate (PEGDA) hydrogel nanoparticies to deliver 
chemotherapeutic agents to highly specific sites, and for use in treatment o f glioblastoma. 
[32]
71.2.2.3 Polymer
Polymeric nanoparticies are developed and are similar in nature to the hydrogel 
nanoparticies. In the same way as hydrogel nanoparticies, the polymeric nanoparticies are 
being made from erodible polymers so when they erode they release an encapsulated 
drug and then disappear. Poly(s-caprolactone), poly(lactic acid), poly(g!ycolic acid) and 
their copolymers are among the polymers under heavy investigation for use in cancer 
therapies. Research on these nanoparticies is focusing on “smart” technologies, which 
similarly to hydrogel nanoparticies, are sensitive to environmental stimuli. Some particles 
will have active targeting toward a specific site and some will be passive targeting, but 
triggered by site-specific conditions to release the encapsulated drug. Active targeting 
will involve ligands and aptamers, and site triggering could focus on pH or thermo­
response. In addition, some particles could be produced with multiple “smart” 
technologies. The use o f polymeric nanoparticies could help in the location specific 
delivery o f chemotherapeutic agents, decreasing systemic toxicity and improving patient 
outcomes. [33]
1.2.2.4 Iron Oxide
Ultrasmall superparamagnetic iron oxide (USPIO) nanoparticies have been evaluated 
for use as an enhancement for magnetic resonance imaging (MRI). This contrast agent 
would provide information to assist in the staging o f axillary lymph nodes in breast 
cancer patients. The Dextran-coated USPIOs demonstrated a half-life of 36 hours. The 
use as a contrast agent due to uptake in normal lymph node macrophages and a lack of 
uptake in tumor cells. [34]
81.2.2.5 Gold Nanoshells /  Nanorods
Gold nanoshells are spherical particles with a dieletric core with a thin gold shell. The 
ratio o f core to coating gives the nanoshell’s tunable optical properties. [35] Gold 
nanoshells (diameter o f approximately 155 nm) and nanorods (14 x 45 nm) have 
demonstrated utility in cancer therapies through the use of the tunable optical properties. 
One therapy involves the intravenous injection o f gold nanoparticies and passive 
accumulation in tumor tissue. Once accumulation is complete the particles are exposed to 
a specific wavelength o f light (by fiber optic), which excites and heats the nanoparticies, 
killing the tumor. This photothermal ablation o f the tumor has, two major advantages: 
killing the tumor along vascular lines (cutting the tumor off from its source of nutrients) 
and preferentially killing the tumor minimizing damage to healthy tissue surrounding the 
tumor. Once the tumor dies, the cells are disposed o f by the immune system. [35]—[38]
1.3 Research Need & Presented Research
A goal for this research is to discover needs, and create specifications driven 
research to solve problems in pre-clinical and clinical implementation o f gold 
nanoparticle driven therapies. This research is designed to answer questions about the use 
o f gold nanoparticies that are applicable to clinical trials in the future. The results o f each 
unique experiment will be used to construct a standard one compartment pharmacokinetic 
model. The use o f near real-time pharmacokinetics will give us a unique and faster look 
at the physiological response to nanoparticies, giving us the ability to more rapidly make 
recommendations on treatments. Through these experiments, we will work to use 
pharmacokinetic parameters and models to make recommendations and create a set of 
“best” practices in cancer nanomedicine. These “best” practices should include a set of
9standardized guidelines and specifications (shown in Table 1-1) to help in the design and 
use o f nanomaterials and implementation o f near real-time pharmacokinetics.
Table 1-1: Real-world needs found during experimentation and design specifications of 
implemented solutions.
Reliable Review of Data Quality Save data for offline analysis
Uniform Data Output
MATLAB code for data 
quality review and creation of 
graphs and PK metrics
Loss of high quality pulsatile 
signal
Prevent loss of peripheral 
circulation by discontinuing 
anesthesia and keep animal in 
warm ambient environment
Ability for Rapid Blood Plasma 
Concentration Reading Less than 5 minutes
NP Stains on Tail Interfere With 
NanoTracker Readings
Injection rate set to 
<18pL/min
Tumor Uptake Data in Clinically 
Relevant Time Frame Analyzed in less than 12 hrs.
Minimal Sample Prep for 
Elemental Analysis
Minimize "skilled" tasks to 
pipetting
Extended Circulation 
Nanoparticies
4-48 hr. maximum 
concentration in tumor
PK Metrics did not predict 
uptake
Quantify additional 
potentially important 
variables
Large Variation in maximum 
blood plasma concentration
Achieve ±10% of injection 
goal with 95% precision
The body o f research presented in this dissertation is the product o f iterative and 
tangential improvements to rapidly develop protocols for use in translational pre-clinical 
trials using gold nanoshells and nanorods in conjunction with clinical trials on gold
nanoshells. The flow o f these experiments is shown in Figure 1-1, and the evolving list of 
real-world needs and design specifications.
U*t of Real-Tim* 
Phatmacokinst-
ict
Initial Experiments
Protocol 
Review:
Hyperthermia and 
Long vs Short
Energy 
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X-Ray 
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U n  of Reel-Time
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Revised Experi­
ments
Mathematical
Modeling:
Monti C arlo
Mathematical
Modeling:
Controls
RES Blockade 
and Redosing
Observations of 
Cofactors on 
Preaction of 
Uptake
Injection
Normalization
Figure 1-1: Flowchart to visualize experimental development.
The work started with a review of the standing pre-clinical protocols to 
familiarize researchers with the protocols and make observations o f improvements 
(CHAPTER 4: Animal Protocol Review Using Gold Nanoshells). The recommendations
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from this review were integrated into the work of both iterations o f CHAPTER 6: Use of 
Real-Time Pharmacokinetics to Predict Tumor Uptake o f Gold Nanorods. The initial 
experiments of CHAPTER 6: Use o f Real-Time Pharmacokinetics to Predict Tumor 
Uptake o f Gold Nanorods revealed a need to develop a rapid elemental analysis system to 
be able to observe a full set o f data on one animal prior to the beginning o f an experiment 
on another animal (and for future clinical work). This need for a rapid elemental analysis 
system lead to the work in CHAPTER 5: Development o f an Energy Dispersive X-Ray 
Fluorescence (EDXRF) Technique for Elemental Analysis o f Gold Nanorods, and this 
novel rapid elemental analysis technique was used in the revised experiments o f 
CHAPTER 6: Use o f Real-Time Pharmacokinetics to Predict Tumor Uptake of Gold 
Nanorods. The data from these revised experiments was used in three unique paths:
1) Can a control feedback system be created to control the injection phase? 
(Section 3.2: Mathematical Modeling- Controls)
2) Can adjuvant therapies affect the circulation pattern of nanorods during the 
accumulation phase? (CHAPTER 8: Reticuloendothelial System Blockade 
and Redosing o f Gold Nanorods in a Murine Model)
3) This data set was used as experimental data for the confirmation o f the Monte 
Carlo model presented in section 3.1: Mathematical Modeling- Monte Carlo.
The Monte Carlo model presented in section 3.1 suggested some parameters (pore 
size, particle size, blood plasma concentration o f NPs, and blood pressure) o f the model 
could affect the delivery o f NPs to a solid tumor. Some o f these parameters became the 
focus o f our next study: CHAPTER 7: Observation o f Cofactors on Prediction o f Tumor 
Uptake of Gold Nanoshells.
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The large variation o f observed peak NP blood plasma concentration in the 
Observation o f Cofactors on Prediction o f Tumor Uptake o f Gold Nanoshells CHAPTER 
7), development o f the control feedback system (Section 3.2), and the study o f 
Reticuloendothelial System Blockade and Redosing o f Gold Nanorods in a Murine 
Model (CHAPTER 8) demonstrated a need for more uniform delivery o f NPs. This need 
for uniform delivery spurred the need for improved injection protocols (Section 10.1) and 
to make uniform delivery by observed blood plasma concentration enabled by the 
NanoTracker (CHAPTER 9: Injection Normalization). These studies combined have led 
to the development and improvement o f pre-clinical protocols for the utilization o f real­
time blood plasma concentrations to improve the development o f individual and 
population pharmacokinetic models o f gold nanoshells and nanorods in a murine model.
CHAPTER 2
LITERATURE REVIEW
2.1 Gold Nanoshells and Nanorods
The gold nanoparticies (nanoshells and nanorods) discussed in this dissertation 
are provided by Nanospectra Biosciences, Inc. (NBI). Their nanoshells are currently in 
multiple pre-clinical and clinical trials under an investigational device exemption (these 
nanoparticies do not chemically interact with the body and are therefore classified as 
devices, not drugs). The nanoshells are approximately 150 nm in diameter with a mPEG 
coating, stored in an iso-osmotic solution o f 10% trehalose, and produced in the manner 
described by Oldenberg and colleagues. [39], [40] Biodistribution of these gold 
nanoshells has been conducted, and will not be evaluated in the experimental section of 
this dissertation. James and colleagues demonstrated that at 1 day the gold was primarily 
found in the organs o f the RES (Liver- 311 PPM, Spleen- 1890 PPM). [40]
The gold nanorods provided by NBI are approximately 15 x 45 nm, PEGylated, 
and suspended in an iso-osmotic solution o f 10% trehalose. The nanorods are synthesized 
using a modified version of the method developed by Jana and colleagues [41] described 
by Goodrich and colleagues . [37] Biodistribution o f these gold nanorods has been 
conducted, and will not be evaluated in the experimental section o f this dissertation. 
Goodrich and colleagues demonstrated the primary accumulation of gold after one day
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was in the organs of the RES (liver approximately 77% of injected dose and spleen 
approximately 6% of injected dose). [37] Tucker-Schwartz and colleagues used 
photothermal optical coherence tomography and PEGylated gold nanorods o f similar size 
(synthesis roots that trace back to Jana and colleagues [41] through Murphy and 
colleagues [42]) to monitor the accumulation and dissipation in mammary tumors, and 
found the maximum accumulation to be at 16 hours. [43]
2.2 Clearance of Gold Nanoshells and Nanorods
Nanoparticies are subject to rapid opsonization by complement and other proteins. 
This opsonization is followed by removal from the blood by hepatocytes (particularly 
particles <100nm) and macrophages of the reticuloendothelial system (RES) within 
seconds o f injection (creating short half-lives incompatible with passive targeting). [44], 
[45] The Kupffer cells (tissue macrophages o f the liver) are unable to directly detect 
foreign bodies in the blood, so this process requires the opsonization of the nanoparticies 
while they are circulating. Opsonins found on liposomes (a nanoparticle o f similar size 
and shape to gold nanoshells) fall in two categories: immune opsonins and non-immune 
opsonins. Immune opsonins include immunoglobulins, complement-related proteins (C- 
reactive protein, serum amyloid P, or mannose-binding protein) and components of the 
complement system (such as C3, C4 and C5); non-immune opsonins include serum 
proteins (such as albumin, a2-macroglobulin, apolipoproteins, laminin, fibronectin, etc.). 
[44], [45]
The interactions o f complement and liposomes have been investigated but never 
fully understood. Some of the approaches taken to investigate these interactions include 
measurements in plasma complement levels (through systems like ELISA and
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radioimmune assays) or changes in liposome structure (by release o f a drug or molecule 
from the liposome); the latter demonstrates fewer parallels to gold nanoshells. Multiple 
studies have demonstrated the activation o f complement through the classical pathway, 
through both antibody-dependent and antibody-independent methods. Some studies have 
demonstrated a difference in activating the classical or alternative pathway dependent on 
cholesterol content o f the liposome. Scieszka and colleagues have demonstrated 
opsonization dependent on heat-labile serum components, and that C3bi was responsible 
for opsonization and uptake was enhanced by C5a. C3bi protein was proven responsible 
through experiments using serum-lacking C3. The activation o f the complement system 
through intravenous injection o f liposomes has also demonstrated sever anaphylactic 
reactions. These reactions can be mediated through improving administration techniques 
(such as adjuvant therapies or injection rate). [45]
Once a particle has been opsonized one o f three methods are commonly used to 
make the phagocytic cells recognize the particle. The first method involves 
conformational changes o f attached opsonin proteins from an inactive to an active protein 
that is recognized by the phagocytic cells. The second method involve the attachment o f a 
phagocyte to the particle by non-specific adherence to blood serum proteins. The third 
method involves the activation o f phagocytes attracted to the activated complement 
proteins attached to the particle. [44]
2.2.1 PEGvlated Nanoparticies
Charged and hydrophobic particles are more rapidly and efficiently removed by 
the reticuloendothelial system, compared to electrically neutral particles. This high 
removal rate created a need to make the particles electrically neutral or hide the particles
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by adding a surface coating. [27] Masking nanoparticies from the RES is necessary to 
increase the circulation time to a period long enough for passive accumulation. This need 
created a group of “stealth” nanoparticies. The most common surface coating for stealth 
nanoparticies is polyethylene glycol (PEG). A form o f PEG (DSPE-PEG) has been used 
to demonstrate a concentration dependent suppression o f opsonizing proteins, and chol- 
PEG or PE-PEG have been used to demonstrate a concentration dependent ability to 
inhibit binding o f C lq  with the ability to almost eliminate the binding at high enough 
concentrations. [45] PEG uses steric hindrance to prevent the adsorption o f opsonins and 
delaying the uptake by phagocytic cells. PEGylation o f nanoparticies is a common 
method of evasion o f the immune system and used in liposomes, polymeric nanoparticies, 
gold nanoshells, and gold nanorods. PEG has several problems including liposomes 
demonstrating a lower tumor accumulation compared to non-PEGylated liposomes, and 
PEG is responsible for the accelerated blood clearance found upon repeated injections of 
PEGylated nanoparticies. Given the known problems with PEG, other surface coatings 
(Polyoxazolines, Poly(amino acids), HPMA, Polyetaines, Polyyglycerols, or 
Polysaccharides) should be considered. [27]
2.2.2 Accelerated Blood Clearance (ABC)
Upon repeated injections of PEG liposome, a significantly shorter circulation half-life 
was noted; if the repeated injections were given after a long enough delay the 
pharmacokinetics returned to a similar to normal state. This phenomenon could be 
transferred to other mice through transfusion o f serum, suggesting a soluble serum factor 
was the cause. [46], [47] Some studies point to PEG as the source o f the ABC 
phenomenon, however a change in PEG (density or length) can prevent ABC. [45] The
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importance o f this phenomenon depends on the use o f the particular nanoparticle. If the 
therapy is a one shot therapy, i.e. if the therapy can only be used once, it is not important 
what the immune response would be to repeated injections. In the case similar to the 
repeated doses of DOXIL administration should be spaced appropriately to improve the 
therapeutic index. [47]
2,2,3 Anti-PEG Immunoglobulin
Studies have suggested, through experimentation using “empty” PEGylated 
liposomes, that a peg specific IgM (known to exist since 1983) contribute to the ABC 
phenomenon. [48], [49] Ichihara and colleagues suggest that the mechanism responsible 
for ABC could be anti-PEG IgM released after the initial dose of PEGylated particles 
binds to a subsequent injected dose o f particles. When the IgM attaches to the second 
dose of particles, the complement system is activated and the opsonization o f particles 
that have activated C3 fragments. The attachments o f complement and IgM create a rapid 
clearance o f the particles through the Kupffer cells o f the liver. [50]
Experiments have found PEG acts as a type two T cell-independent antigen and 
primes the B cells in the marginal zone o f the spleen. This result was found through 
elimination of marginal zone B cells through the use o f cyclophosphamide. The T cell- 
independence was discovered through the use o f nude mice. Marginal zone lymphocytes 
were eliminated through the use o f cyclophosphamide eight days prior to the injection of 
liposomes and serum was collected five days after the injection o f liposomes. ELISA 
procedures were used to investigate presence o f IgM and IgG, which demonstrated a low 
level o f anti-PEG IgM and IgG (implying the importance o f the marginal zone B cells in 
production of anti-PEG immunoglobulins). A separate study showed anti-PEG IgG at
three to five days and anti-PEG IgM three to ten days after the injection o f liposomes, 
with a peak concentration around five days. Both IgM and IgG levels returned to normal 
by fourteen days after the initial injection o f liposomes. The investigation of 
immunoglobulin response in the absence o f T cells was conducted using nude BALB/c 
mice, and demonstrated anti-PEG IgM ten days after the initial injection o f liposomes. 
Implying a T cell-independent mechanism for the production of anti-PEG IgM. [48]
Through experimentation, Ishida and colleagues were able to establish a T cell- 
independent anti-PEG IgM response. This finding was discovered when anti-PEG IgM 
was found in nude mice and not in SCID mice, suggesting the important mechanisms for 
creation o f anti-PEG IgM were in the B-cells and not in the T-cells. Additional injections 
o f liposomes did not cause isotype switching from IgM to IgG. These findings support 
PEG acting as a type two T cell-independent antigen, and contribute to the current 
understanding that B cells o f the spleen are the critical component in the ABC 
phenomenon. The T-cell independent antigens (PEGylated particles in this case) did not 
induce memory B-cells that produce IgG, explaining the loss o f the ABC phenomenon 
given enough elapsed time from initial injection to subsequent injection. Testing for T 
cell-independence involved testing using three groups o f mice: normal, nude, and SCID 
mice. The levels o f serum immunoglobulin was similar in normal and nude mice, but for 
all practical purposes absent in SCID mice, suggesting the T cell-independence. 
Experiments conducted to suggest the importance o f the spleen involved the removal of 
the spleen from rats and subsequent injections o f liposomes; results showed 
immunoglobulin production was reduced in rats with no spleen. Liposomes were 
repeatedly injected at seven day intervals to demonstrate the T cell-independence o f PEG
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as an antigen. This study showed the first injection to result in the maximum anti-PEG 
IgM production, limited isotype switching, and no generation o f B cell memory; 
implying, T-cell independence. Serum samples for all the experiments were collected five 
days after injection of PEGylated liposomes and separated by centrifugation using serum 
separating agents. [50]
Studies have been conducted to elucidate if ABC is caused by an increase in 
phagocytic activity of liver macrophages or if an increase in efficiency o f opsonization is 
to blame. Rat livers were perfused with PEGylated liposomes designed to cause optimal 
ABC. With the absence o f serum in the solution, no improved liver uptake was noted. 
This finding suggests the liver uptake is not changed but the opsonization is. In addition, 
procedures were followed to heat treat the serum; the results demonstrated a lower 
serum-dependent liver uptake. These findings demonstrate the first dose of PEGylated 
liposomes do not increase the activity o f the Kupffer cells, and complement activation is 
responsible and essential for ABC. [51 ]
2.3 NanoT racker
The NanoTracker is a non-invasive device developed to give near real-time 
optical monitoring o f intravascular nanorods and nanoshells. This device works on the 
same basic technology as a pulse oximeter, pulse photometry. Michalak and colleagues 
says “We develop a pulse photometer capable o f accurately measuring the 
photoplethysmogram in mice and determining the ratio o f pulsatile changes in optical 
extinction between 805 and 940 nm, commonly referred to as R. these wavelengths are 
selected to correspond to the extinction properties of gold nanoshells”. [23] Michalak and 
colleagues later describes the instrumentation involved, “Our device consists of a probe
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compatible with mouse anatomy, analog circuitry, a data acquisition card, and LabVlEW 
software”. [23] The probe includes an LED that emits at four unique wavelengths (660, 
735, 805, and 940). This LED is purchased through Marubeni out o f Santa Clara, 
California. Only the 805 and 940 nm wavelengths are used in the probe. A photodiode 
(Hamamatsu Hamamatsu City, Japan) is used on the other side o f the subject to record 
the changes in emitted light through the subject. The additional analog circuitry consists 
of filtering and timing systems, among other things.
The NanoTracker, a multispectral pulse photometer, is commonly used for mice 
under light anesthesia or no anesthesia to detect the intravascular concentration of 
nanorods. The NanoTracker helps by providing the levels o f nanoshells or nanorods in 
the vasculature, displayed as optical density. The NanoTracker does this by observing 
pulsatile changes in optical extinction between 805 and 940 nm, and calculating a ratio 
between the wavelengths known as R shown in Eq. 2-1, where VAc is the alternating 
current voltage, VDC is the direct current voltage, Aj is wavelength 1, and A2 is 
wavelength 2. [23]
The NanoTracker then simultaneously solves Eq. 2-2 and Eq. 2-3 to solve for the 
optical density of the nanorods (ODNR) and oxygen saturation (5), using the R values, 
effective attention coefficients o f oxygenated whole blood (Mh&o2) at wavelength (A), and
Eq. 2-1
effective attention coefficients of deoxygenated whole blood (/iHbo2) at wavelength (A).
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The use of the NanoTracker allows us to obtain as many data points on the blood 
plasma concentration curve as we would like, rather than being restricted by the amount 
o f blood we can safely draw from the mouse for ex vivo optical density measurements. 
This ability to obtain as many data points as desired is advantageous so we build a more 
reliable blood plasma concentration curve. Another main advantage o f the NanoTracker 
is the potential for use in near real-time applications o f pharmacokinetic models and 
feedback controls during nanoparticle infusion.
2.4 Pharmacokinetics
“In Brief, pharmacokinetics is concerned with quantitatively accounting for the 
whereabouts of a drug after it has been introduced into the body. The analysis is carried 
out through the entire time course for the drug in the body”. [52] The importance of 
pharmacokinetics is not always apparent; however, until the full biodistribution of 
nanorods is fully understood we will not be able to even speculate at what toxicity problems 
could be faced. Even basic pharmacokinetic modeling is not a trivial task. This section 
discusses two basic models, the one compartment and population pharmacokinetic models. 
More advanced model such as a physiologically based models would be beneficial for a 
better understanding o f the biodistribution. Physiologically based pharmacokinetic models 
typically include significantly more compartments to account for more biological systems. 
De Jong and colleagues conducted biodistribution studies, and demonstrated a presence o f
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gold nanoparticies (of multiple sizes) in the blood, liver, spleen, lung, brain, heart, and 
kidney at 24 hours. [53]
2.4.1 One Compartment Model
A one compartment non-physiologically based model, shown in Figure 2-1, is 
currently being used due to the availability o f data. The one compartment model for the 
experimental data would represent the blood volume o f the mouse. Concentration of 
nanoparticies in the blood volume o f the mouse is available in the form o f experimental 
data. The blood volume in a twenty-gram mouse is approximately 1.44 mL or 72 ml/kg. 
The model uses Eq. 2-4 to give a concentration as a function o f time.
Nanoparticle InjectionN Compartment One Volume = V 
Concentration = C
Clearance (K j
Figure 2-1: Box Diagram demonstrating one compartment model.
C =  C0e~ket Eq. 2-4
Where C is the concentration, C0 is the initial concentration, ke is the elimination 
rate constant, and t is time. The initial concentration is calculated using Eq. 2-5.
Cn = ——  Eq. 2-5
0 VOD H
Where D is the initial dose and VOD the volume o f distribution. Using this basic 
model the half-life (tiy2) is calculated using Eq. 2-6.
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ln(2) 0.693
Eq. 2-6
k e k e
This model demonstrates the removal o f the nanoparticies from the blood as a 
function of time. This model does not account for differences in the accumulation or release 
of nanoparticies from tissues, but only the overall removal o f the nanoparticies from the 
blood.
Other models, such as two compartment physiological models, would provide a 
better model o f the movement o f nanoparticies. These models would depend on the 
availability o f real-time data reflecting accumulation in target tissues.
2.4.2 Population Pharmacokinetics
Population pharmacokinetics (popPK) investigate the variability between subjects 
given the same treatment, also referred to as inter-subject variability. The focus of popPK 
involves studying and attempting to account for the inter-subject variability in terms o f 
subject specific variables, such as age, sex, or weight. Studies often do not collect enough 
data for the pharmacokinetic parameters of an individual to be calculated. This lack of 
available data has skewed the meaning of popPK to focus on analysis involving scarce 
data. The developed popPK analysis techniques are applicable to studies with ample data, 
but become a more valuable source of analysis in studies with scarce data. The nature of 
sparse data does not allow for traditional analysis techniques. The need for novel analysis 
techniques created several approaches such as nonlinear mixed effects modeling (Beal & 
Sheiner 1982), non-parametric maximum likelihood (Mallet 1986), Bayesian (Racine- 
Poon & Smith 1990). Nonlinear mixed effects modeling is the most popular method, due 
in part to the software package NONMEM. [54]
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The title popPK conspicuously points toward the primary focus o f the analysis 
techniques, populations not individuals. [54] This focus is a counterintuitive connection 
with nanomedicine, where the focus is individualized medicine. However, the ability of 
popPK modeling to reveal sub-group specific effects (observed through covariates) can 
help the clinician choose have more realistic expectations o f treatments should start to 
obtain the desired outcome.
2.5 Elemental Analysis
Experimental studies in nanomedicine employ different types o f metal 
nanoparticies. For example, gold nanoparticies are being used in animal and human trials 
for assessing the feasibility of photothermal ablation o f inoperable solid tumors. [21], 
[35], [55] A potential way to enhance efficacy in such cancer therapies is to increase 
feedback through additional clinical signs during the accumulation and treatment phases. 
Nanoparticle systems could be coupled with individualized pharmacokinetics and 
elemental analysis o f ex vivo tissue to confirm uptake and retention into the tumor. 
Concurrently, innovative medical devices are being developed to provide near- 
instantaneous pharmacokinetic feedback, [23], [36] suggesting the need for an elemental 
analysis technique that provides similarly rapid quantitative feedback o f biodistribution. 
These analyses could assess when, and to what degree, the particles were accumulating in 
the tumor, or if they were being eliminated by the RES. The use o f rapid elemental 
analysis coupled with real-time pharmacokinetic [23], [36] measurements could help 
predict the most appropriate time for animal or human ablation (e.g. photothermal) of the 
tumor. For animal studies, a faster technique can have a major impact for companies 
involved in nanomaterial quality control and product development. For human trials, the
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ability to measure, or predict, the accumulation o f the nanoparticies in the target tissues 
could improve treatment outcomes for some o f the approximately 52,000 anticipated 
deaths due to cancers targeted by this therapy each year, in the United States. [ 1 ] 
Biodistribution of gold nanorods is normally analyzed through inductively 
coupled plasma mass spectrometry (ICP-MS) or instrumental neutron activation analysis 
(1NAA). [30], [37], [40] ICP-MS requires elaborate and time-consuming sample 
preparation (up to 104 hours). [56] INAA does not require a long sample digestion and 
preparation, but requires longer analysis. [40] Although both o f these techniques are 
accurate, they take from days to weeks to get results, longer than a clinical treatment time 
o f one day. If the data were available within the clinical treatment time, we hypothesize 
that some accuracy could be sacrificed compared to these standard methods.
Energy Dispersive X-Ray Fluorescence (EDXRF) is a technique used for bulk 
and ppm elemental analysis that is rapid, robust and requires little sample preparation 
time. [57] EDXRF has been previously used for quantitative in vivo and ex vivo analysis 
o f gold in tissues like kidney and liver. [58], [59] Previous work with biological samples 
demonstrates the need for thin samples, so that matrix effects can be neglected. [60] 
Common EDXRF protocols require a long process of drying, crushing, and pressing 
samples into pellets. [60], [61] Based on guidance from the literature towards optimizing 
a rapid sample preparation, the key aspects o f this protocol include: sample thickness, 
geometry, and homogeneity. [60]
CHAPTER 5 outlines the procedure developed for a benchtop EDXRF elemental 
gold analysis o f gold nanorods (~ 15 x 45 nm), an optically absorptive cylindrical nano­
object used in nanomedicine. [37], [62] The protocol presented in CHAPTER 5 includes
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tissue digestion/homogenization in potassium hydroxide followed by desiccation in the 
sample cup before EDXRF analysis. Using subcutaneous mouse tumors, the elemental 
analysis was completed in less than 12 hours from the time o f tissue collection.
CHAPTER 3
MATHEMATICAL MODELING
The results of CHAPTER 6 demonstrated poorer than expected correlations 
between tumor uptake and standard pharmacokinetic metrics. This less than optimum 
correlation generated a desire to observe additional variables. To find these variables we 
turned to collaborative modeling efforts, and then continued with experimental 
verification in CHAPTER 7.
Many people have used mathematical modeling o f tumor and tumor vasculature 
toward different goals. Jain and colleagues used a model, established by their lab in 1988, 
to study the changes on interstitial fluid pressure based on changes to “normalize” the 
vasculature. [63] Chapman and colleagues used their modeling efforts to examine the 
fluid flow through the leaky vasculature o f the tumor. [64] Frieboes and colleagues used 
a mathematical model to understand some o f the variables that may help to explain tumor 
growth and invasion. [65] Howard and colleagues demonstrated the use o f the unit 
density sphere model as a practical alternative for clinical use compared to the 
computationally demanding but more accurate Monte Carlo algorithms. [66] Soltani and 
colleagues used a computational fluid dynamics simulation based on previous works to 
study some o f the changes in pressure and introduced new parameters in this model. [11] 
Goh and colleagues worked to develop a two-dimensional simulation platform to
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demonstrate the transport of Doxorubicin to hepatomas, an elaboration o f previous work. 
[67]
Goh and colleagues worked to create a two-dimensional simulation from a one­
dimensional simulation. The goal was to be able to explore the special and temporal 
variations of doxorubicin concentrations and the penetration into the tumor and healthy 
tissue. Other areas this model was designed to study are lymphatic drainage, and 
intracellular kinetics. They were able to show that changing the injection volume does no 
result in significant changes in drug concentration in the tumor or healthy tissue. They 
also found that diffusion is the main transport mechanism o f free doxorubicin. Goh says 
that some ways to improve the model would be to test the assumption o f spatially 
independent physiological parameters, for fast growing tumors the boundaries between 
zones should be examined, and the use o f a heterogeneous distribution o f drug molecules 
in the blood. [67]
Soltani and colleagues used previous models and assumed a spherical tumor.
Some o f their assumptions included drug particles flow with the interstitial fluid. This 
study demonstrated an increase in necrotic radius decreases the maximum pressure inside 
the tumor, also they demonstrated that if a tumor is completely necrotic the interstitial 
fluid pressure is zero. They also found that the transport o f a drug into a smaller tumor, 
defined as being below critical tumor radius, is easier than larger tumors. They also 
demonstrated that there is a critical necrotic radius. Above the critical necrotic radius the 
effective pressure is such that it is easier for drugs to reach the center o f the tumor. [11]
The work o f Howard and colleagues is focused on the treatment o f non-Hodgkin’s 
Lymphoma. The model used is trying to demonstrate usefulness for patient specific
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dosimetry-based treatments. This planning requires an accurate assessment o f the 
radiation absorbed by the healthy tissue. The majority o f these calculations are 
predetermined by Monte Carlo algorithms and use a “reference man” for the anatomy. An 
optimal situation would allow for 3D imaging o f the patient to be used in the Monte 
Carlo algorithm rather than the “reference man.” They have created a unit density sphere 
model incorporated in previously established models. This ideal situation would create an 
extremely calculation heavy treatment system, therefore becoming less clinically 
available. The conclusions o f this study show the sphere model is more applicable due to 
the lower computational needs, but can be less accurate and therefore not useful in all 
applications. [66]
The work o f Chapman and colleagues focuses on modeling the fluid flow through 
the capillary o f a tumor. Their model describes fluid flow through solid tumors, and uses 
a number of different capillary lengths. Some o f the assumptions they used in their model 
include using blood as a Newtonian fluid, where the model could be improved by using 
blood as a shear-thinning fluid. Other assumptions that they used and could be changed to 
improve the model include the viscosity o f blood. They claim that as the plasma leaks out 
of the capillary it would alter the hematocrit and therefore change the viscosity; this 
change would create a need for additional feedback in their model. They also suggest that 
their model could be improved if further work included a pressure-dependent capillary 
radius. [64]
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3.1 Monte Carlo
Mathematical modeling o f tumor and tumor vasculature have been proposed and 
implemented to address different goals. With their model established in 1988 [68], Jain 
and colleagues studied the effect o f antiangiogenic agents on the tumor IFP. [63] The IFP 
of various tumors was calculated based on the transport properties o f the capillary wall 
and interstitium and a decrease in the IFP of the tumors after antiangiogenic treatment 
was reported. The decrease in IFP occurs because the capillary walls are less permeable 
than before the treatment. From the point o f view of the nanoparticle-based treatment, 
this imposes a trade-off between a more efficient delivery due to a larger pressure 
gradient from the capillary to the tumor, but through a less permeable wall. The fluid 
flow through the leaky vasculature o f the tumor was also studied using modeling. [64] In 
that model, the flow along the capillaries, across the capillary walls, and through the 
interstitium were described by Poiseuille’s [25], Starling’s [69], and Darcy’s laws [70], 
respectively. However, in their study the authors treated blood as a Newtonian fluid.
Frieboes and colleagues used a mathematical model to understand some o f the 
variables that may help to explain tumor growth and invasion. [65] Soltani and Chen [11] 
developed a numerical model to study the fluid flow in the tumor interstitium where the 
tumor tissue was assumed to be spherical and the fluid flow was governed by 
conservation of mass and momentum. They studied the fluid velocity and interstitial fluid 
pressure as a function o f the tumor size. Chang and colleagues, developed a network 
model to study the delivery of colloidal drugs [9] where the tumor interstitium was 
represented by a 2-D square network while the movement o f colloidal particles in the 
interstitium was simulated by the Brownian dynamic simulation method. Drug delivery
for different drug concentrations and different interstitial pressures was studied in that 
work.
Models to predict nanoparticle transport and uptake in tumor tissue have also been 
discussed in the literature. Goodman and colleagues [71] developed a mathematical 
model o f nanoparticle transport in a non-uniform porous spheroid representing a tumor. 
Nanoparticle diffusion into spheroids and particle binding and dissociation at the cell 
surface was modeled. The effect o f the number o f binding sites and pore distributions in 
the spheroid on the nanoparticle transport and accumulation is studied. Nanoparticle 
accumulation was predicted to be non-uniform but correlated with the porosity o f each 
region in the tumor model. Styiianopoulus and colleagues [72] developed a methodology 
to calculate the diffusion coefficients o f macromolecules and nanoparticles in 
collagenous tissues resembling the interstitium. The tissues were modeled as three- 
dimensional, stochastic, fiber networks with varying degrees o f alignment. The study 
predicted that the structure and orientation o f collagen fibers in the extracellular space 
affects the isotropy o f nanoparticle distribution, with more aligned fibers resulting in a 
more anisotropic distribution. Frieboes and colleagues [73] modeled the accumulation o f 
nanoparticle in tumor vasculature at different tumor stages. Their model simulates the 
growth o f cancer tissue and predicts the accumulation o f nanoparticle in its vasculature 
for different sized nanoparticle. They predict that increasing the affinity o f nanoparticles 
for vessels results in their accumulation at the tumor inlet leading to a poor delivery to the 
tumor core and outlet vessels; in contrast, reducing the vascular affinity produces a more 
uniform nanoparticle distribution but also reduces the overall nanoparticle delivery. 
Mishra and colleagues [74] on the other hand, study the tumor response to the
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nanoparticles delivered. Their model describes the nanoparticle concentration in the 
tumor cell and the tumor cell movement. Their model predicted an exponential reduction 
of tumor size as a long-term response to the treatment for both 10 nm and 100 nm 
nanoparticle. The effect of nanoparticle’s shape and size has also been addressed, [75] 
reports experimental evidence that size, shape, and surface properties all play a role in the 
nanoparticle accumulation in the vasculature with 1000 nm x 400 nm plateloids being 
predicted to provide a rapid and larger than ever reported before accumulation of 
nanoparticle in tumor. A mathematical model is then used to predict the probability of 
nanoparticle adhesion to the blood vessel that shows maximum adhesion for nanoparticle 
o f 1000 nm in size in agreement with the experiment. The model also predicts that lateral 
drifting diminishes with size and it is smaller for spherical than for anisometric 
nanoparticle, as lateral drifting allows periodic interactions with the lateral wall, show 
smaller and more symmetric nanoparticles lower accumulation
The objective o f the computational model developed by the Derosa group is to 
track nanoparticles in the blood stream and into the tumor through the capillary wall and 
to predict nanoparticle delivery as a function of controllable parameters that can be 
adjusted to optimize the delivery. [28] Nanoparticle transport is obtained from the 
velocity of the blood flow over imposed with Brownian motion. The blood vessel in the 
model is designed as a cylindrical tube with a single pore o f a size in the range o f the 
tumor capillary wall pores. This model is able to predict the dependence o f the 
nanoparticle’s delivery to the tumor tissue on blood pressure, interstitial pressure, size, 
and concentration of nanoparticles in the blood stream, and pore size. The model 
incorporates the parameters that characterize tumors and distinguish them from normal
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tissue (such as high IFP and larger pore size), and simulates nanoparticle flow through 
the capillary wall as an extravasation event. Since drug and medical device development 
relies on design specifications that meet end-user needs and integrate a process for 
evaluation o f performance metrics, the model presented here seeks to serve as a tool to 
predict the effect of relevant parameters on the uptake o f medical nanoparticles, and thus 
provide parameters that can be used for future designs.
A model to simulate nanoparticle delivery to leaky solid tumors is presented. The 
study indicates that nanoparticle delivery increases with pore size. Hyperthermia [76], or 
any other mechanism which increases the pore size in the tumor blood vessel wall, is 
predicted to increased drug delivery. Smaller particle size leads to the same effect of 
increasing delivery; however, deliver is found to be more sensitive to pore size than to 
particle size. The reason is that in addition to increasing the pore/nanoparticle size ratio, 
the velocity o f the fluid entering the pore increases with pore size, thus increasing the 
drag force. This effect has been observed in the velocity profile near the pore. Increased 
concentration of the nanoparticles in the blood leads to a linear increase in the number of 
nanoparticles delivered, but the relative efficiency with which they are delivered is 
virtually independent o f the concentration.
The model proposed by the Derosa group [28] and described below shows 
agreement with the experimental information available and produces results that satisfy 
the author’s logic in those cases where no experimental evidence is available. Application 
to other cases leads to provocative predictions, such as the different dependence of 
delivery on nanoparticle size for different tumor IFPs. It was found that the sensitivity of 
nanoparticle delivery to particle size decreases when IFP decreases (increasing the
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pressure gradient from the capillary to the tumor). For the case studied here, for instance, 
there is a clear decrease in nanoparticle delivery with size until an IFP o f about 18 
mmHg; for lower IFP, the delivery is virtually insensitive to particle size. The same effect 
is observed as blood pressure increases, due to the same reason that the pressure gradient 
across the pore increases. All of these predictions would benefit from experimental 
verification and the authors expect this paper can motivate those experiments.
Although the collective effect o f delivery through several pores is an aspect of 
this process that has not been considered in the work, this can be treated as the 
cumulative delivery through one pore at a time by appropriately adjusting the 
nanoparticle concentration. However, IFP changes as blood flows in the tumor will need 
to be taken into account, where large doses are to be simulated, any large accumulation of 
particles may change the IFP, and thus studies o f the interstitium are called for.
Predictions of total doses delivered to a tumor can be obtained by taking into 
consideration the decrease in nanoparticle concentration as they flow down the blood 
capillary.
Finally, it is important to mention that nanoparticle aggregation, if the aggregate 
are numerous enough and make it to the capillary, will certainly affect nanoparticle 
delivery, as shown in this work. Although particle size is a factor in delivery and 
aggregation will lead to much larger particles, nanoparticle aggregates formed within the 
body are quickly removed from the blood circulation by the liver and spleen. [77], [78] 
Aggregates would circulate for such a short period of time that their presence in the 
capillary bed could be neglected. Hence, nanoparticle aggregations are not considered in 
the model.
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The Monte carol model developed by the Derosa group was designed to simulate 
a blood capillary with one pore. The nanoparticles used were spherical in shape and 
similar to the gold nanoshells discussed in CHAPTER 4 and CHAPTER 7 (given the 
correct size). The NPs were acted upon by two forces, the flow o f blood and Brownian 
motion. The flow o f blood was modeled using a pressure-driven flow model o f a non- 
Newtonian fluid in a cylindrical tube with “sticky” walls, which provided a parabolic 
velocity profile with the maximum velocity at the center o f the capillary. The Brownian 
motion component was calculated using randomly assigned distances and angles for 
movement. COMSOL was used to establish a zone where the pore had an effect on the 
movement o f the particles. This zone was established by creating two simulations in 
COMSOL (with and without a pore) and noting the zone where the pore has an effect on 
the fluid flow. The progression o f a NP through the Monte Carlo modeled cylinder is 
outlined in Figure 3-1. The O’Neal group contributed to the work of Podduturi and 
colleagues by providing physiological relevance to the model parameters and 
contributions o f early data for the Derosa group to evaluate the functionality o f the 
model. [28]
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NPs a re  r a n d o m ly d is tr ib u te d  a c r o ss  t h e  c y lin d e r
N Ps are m o v e d  o n e  a t  a t im e  a n d  id e n tif ie d  b y  z o n e ,  
(n o  p a r tic le  is s e le c t e d  fo r  a s e c o n d  t im e  u n til a ll 
h a v e  b e e n  s e le c te d )
| For NP s in 2o n e  2 a t im e  s te p  is d iv id e d  in to  m u lt ip le  
I s m a l le r t im e  s te p s
T h e NP is d is p la c e d  d u e  to  B ro w n ia n  m o tio n
If t h e  NP e n te r s  t h e  p o r e  or  e x its  t h e  b o t to m  o f  t h e  
cy lin d er , a  n e w  H ?  i s  d e liv e r e d  t o t h e  c y l in a e r to  k e e p  
a  c o n s ta n t  c o n c e n tr a t io n
Figure 3-1: Progression o f a NP through the Monte Carlo model. Adapted from the 
work o f Podduturi and colleagues. [28]
This work is unique in the portion o f the nanoparticle delivery system it is 
modeling. The papers discussed and referenced in this section provided background 
information on the state o f mathematical modeling of this system at the time o f this work, 
and provided guidance for parameter values to contribute to the development o f this 
model. The collaborative work between the Derosa and O’Neal groups, in conjunction 
with the data presented in CHAPTER 6: Use o f Real-Time Pharmacokinetics to Predict 
Tumor Uptake o f Gold Nanorods, resulted in a peer-reviewed publication titled 
“Simulation o f Transport and Extravasation o f Nanoparticles in Tumors Which Exhibit 
Enhanced Permeability and Retention Effect”. [28]
3.2 Controls
Collaborative work investigated the use o f a controller with the objective o f 
output tracking. Meaning the controller was attempting to make the blood plasma
3 7
concentration of nanoparticles remain within a desired (assumed) “therapeutic window” 
for the longest time possible with a minimal effort (minimize number o f injected 
particles). The control implementation chosen involved a linear quadratic regulator state 
tracking design. This work used the blood plasma concentration curves from 0 to create a 
“Master Mouse” for each group (A and B) to observe the behavior o f the nanorods. The 
model then continues to use four different injection profiles: linear (constant injection 
rate), positive quadratic (increasing injection with time progress), negative quadratic 
(faster initial rate and slowing with time progress), and an exponential curve. All results 
demonstrated similar total control efforts, but the positive quadratic had the minimal 
effort. [79] This work with a controller will be significantly more interesting once a 
therapeutic window has been established, and we are able to use these control systems to 
target specific AUC values or maintenance in a therapeutic window for a specific time to 
achieve a desired result. These controls will be able to minimize system effort and create 
a constant AUC.
This work is in conjunction with the data presented in CHAPTER 6: Use o f Real- 
Time Pharmacokinetics to Predict Tumor Uptake of Gold Nanorods, and resulted in a 
peer-reviewed conference proceedings titled “LQR Tracking of a Delay Differential 
Equation Model for the Study o f Nanoparticle Dosing Strategies for Cancer Therapy”. 
[79]
CHAPTER 4
ANIMAL PROTOCOL REVIEW USING 
GOLD NANOSHELLS
4.1 Specifications and Introduction
The purpose o f this set o f experiments is to follow and review the established 
protocols. These experiments will inform protocol updates implemented in CHAPTER 6: 
Use of Real-Time Pharmacokinetics to Predict Tumor Uptake o f Gold Nanorods. The 
primary focus these protocol reviews is a retrospective analysis o f the pulse photometer 
data collection and processing, and the need to continue blood draw protocols 
(APPENDIX A: Mouse Blood Draw Protocol). The result of these experiments include 
recommendations for protocol updates to be used in CHAPTER 6: Use o f Real-Time 
Pharmacokinetics to Predict Tumor Uptake o f Gold Nanorods. These experiments are 
broken down into two separate trials: Hyperthermia and Long vs. Short.
4.1.1 Hyperthermia
As part o f a continued effort to decrease injected volume, several parameters are 
being studied to look for changes in circulation times. One o f these parameters leads us to 
study how hyperthermia will affect the circulation time o f nanoparticles. Studies have 
shown that hyperthermic conditions up to 42°C show increased extravasation. [29] The 
previous study looked at hyperthermia over a specific period, where the study presented 
here keeps the subject in elevated ambient environment conditions through the entire
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accumulation phase. Some believe the effect o f temperature difference on the circulation 
time is mainly based on peripheral vasodilatation in hot environments. Regardless of 
mechanism, previous studies have observed pore cutoff size increased to greater than 400 
nm at 42°C. This increase in pore size allowed significant accumulation o f particles up to 
400 nm, when compared to normothermic conditions. [76] With more blood being sent 
through peripheral circulation to dissipate heat more nanorods may be able to avoid the 
macrophages of the RES mainly located in the liver and spleen. However, some studies 
have suggested that fever range hyperthermia could increase immune efficiency. [80] If 
this effect is observed with the RES, the nanorods could be cleared from the blood more 
rapidly. This study was designed to look for observable differences in circulation time 
between the hyperthermic subjects and control subjects.
4.1.2 Long vs. Short
A third study will look into the difference in tumor accumulation and circulation 
time depending on the time over which the injection o f a standard amount o f 
nanoparticles is given. For example, a standard amount o f nanoparticles will be given 
over a period o f less than thirty seconds for one group and another experimental group 
would receive their injections over a period o f ten to fifteen minutes. This study will be 
conducted without tumors then repeated using tumors. The iterations of the experiment 
will provide data on circulation time and tumor accumulation.
4.2 Materials and Methods
All of the studies involve animal work conducted under protocol approved by the 
Louisiana Tech University Institutional Animal Care and Use Committee (IACUC). The
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animals were handled in accordance with the ‘Guide for the Care and Use o f Laboratory 
Animals’.
4.2.1 Hyperthermia
Eight naive BALB/c female mice with intact thermoregulatory systems were used 
to study the effects of hyperthermia on circulation half-life o f experimental gold 
nanoshells (NB1, Houston, TX).
The experimental group o f mice was placed in a forty-two degree Celsius 
environment for a minimum of forty-five minutes prior to injection. The mice were 
anesthetized using isoflurane anesthesia (given at 1 liter per minute at 4% for induction 
and 2% for maintenance), and the nanoshells (a standard dose o f 4.5 pL/g) were injected 
over 10 seconds via tail vein. Once any procedure on the experimental mice was 
completed, the mouse was put back in the forty-two degree Celsius environment.
The control mice were placed in a thirty-six degree Celsius environment for a 
minimum of forty-five minutes prior to injection. The mice were anesthetized using 
isoflurane anesthesia (given at 1 liter per minute at 4% for induction and 2% for 
maintenance), and the nanoshells (a standard dose o f 4.5 pL/g) were injected over 10 
seconds via tail vein. After injection, the mice were kept at room temperature (20-26°C) 
throughout the experiment.
4.2.2 Long vs. Short
Four naive BALB/c female mice with intact thermoregulatory systems were used 
to study the effects o f injection rate on circulation half-life o f experimental gold 
nanoshells (NBI, Houston, TX).
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The experimental group o f mice was placed in a thirty-six degree Celsius 
environment for a minimum of forty-five minutes prior to injection. The mice were 
anesthetized using isoflurane anesthesia (given at 1 liter per minute at 4% for induction 
and 2% for maintenance), and the nanoshells (a standard dose o f 4.5 pL/g) were injected 
over 1 minute via tail vein. Once any procedure on the experimental mice was completed, 
the mouse was returned to housing during the accumulation phase.
The control group o f mice were placed in a thirty-six degree Celsius environment 
for a minimum of forty-five minutes prior to injection. The mice were anesthetized using 
isoflurane anesthesia (given at 1 liter per minute at 4% for induction and 2% for 
maintenance), and the nanoshells (a standard dose o f 4.5 pL/g) were injected over 10 
minute via tail vein. Once any procedure was completed, the mouse was returned to 
animal housing, for the duration o f the accumulation phase.
4.2.3 Intravenous Catheters and Cannulation
Intravenous cannulas were made using 2 French Polyurethane Catheter tubing 
(Access Technologies, Skokie, IL Cat. No BC-2P). On one end, used as the needle for 
vascular access, a 28-gauge needle was removed from an insulin syringe (Tyco/ 
Healthcare '/» mL 28G x Vi' insulin syringe REF # 1188528012, VWR Cat. # 84009-742) 
and attached to the tubing. On the other end o f the tubing a 27 gauge needle (Becton 
Dickinson 27G x Vi' REF 305109, VWR Cat. # BD305109) was added for slip tip or luer 
lock access to the cannula. Injection solution was loaded in a lmL insulin syringe 
(Becton Dickinson 1 mL syringe REF 329650, VWR Cat. # BD329654). Injection 
volume and rate were ensured using a syringe pump (New Era Pump Systems, Inc. 
Farmingdale, NY. Model # NE-1010).
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4.2.4 Temperature Control
Temperature regulation o f the mice prior to injection was achieved using a 
shaking incubator, with the shaker o ff (Labnet International, Inc. Edison, NJ. Model #
21 IDS). During injection and while the mice were under anesthesia the temperature was 
controlled using a heating pad (Physitemp Instruments, Inc. Clifton, NJ. Model # TCAT- 
2LV) and a space heater for ambient air temperature (Sunbeam Products, Boca Raton,
FL. Model #SFH 111).
4.2.5 Gold Nanoshells
PEG modified gold nanoshells were obtained from NBI. The absorption spectra o f 
the nanorods was obtained using a UV/Vis spectrophotometer (Beckman Coulter DU 800 
Brea, CA.). A 1% dilution of nanorods was made using 10% Triton X to obtain the 
absorbance at 600, 805, and 940 nm. These values are required as input values of the 
NanoTracker to ensure proper calculations.
4.2.6 Blood Plasma Concentration Observations
Blood plasma concentration was observed (under isoflurane anesthesia) at 
intervals o f approximately 20 minutes post injection, 90 minutes post injection, end o f the 
first half life, 1.33 half-lives, 1.66 half-lives, and at the end of the second half life. These 
times were based on an assumed six-hour half-life, and altered if an extremely long or 
short half-life was noted. If it was not possible to collect data at those exact times for any 
reason the data point was taken early or late to get as close to the correct time as possible.
4.2,6.1 NanoTracker
Blood plasma concentration was collected using the NanoTracker; data points 
were taken before and after the blood draw. The operator manually recorded the blood
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plasma concentration values, and attempts were made to ensure data was o f sound quality 
(standard deviations less than 0.03, on the mean o f an averaged 5 seconds o f data).
4.2.6.2 Blood Draw Protocol
The blood plasma concentration was confirmed using an established ultraviolet- 
visible spectroscopy (UV/Vis) protocol (APPENDIX A: Mouse Blood Draw Protocol). 
The blood for the UV/Vis protocol was collected by snipping the end of the tail and 
collecting five micro-liters of blood using a pipette coated in Ethylenediaminetetraacetic 
acid (EDTA).
4,2,7 One-Compartment Pharmacokinetic Model
The data from each mouse was manually entered to a spreadsheet and plotted. The 
data was assumed to fit a standard one-compartment pharmacokinetic model; an 
exponential trend line was added and used to calculate relevant pharmacokinetic metrics.
4.3 Results
Table 4-1 displays the half-life for each mouse involved in the hyperthermia study 
for data collected from both the NanoTracker (NT) and absorbance spectrometry 
(UV/Vis). Both groups demonstrated similar half-lives; a t-test was used to demonstrate 
strength o f the similarity between the two groups. The number o f mice in each group 
suggests that a t-test is not fully applicable in this situation, but it is simply being used to 
demonstrate the strength of the similarity between these two groups. The third column 
(the second UV/Vis) excludes the data for mouse 1. This piece o f data causes a 22% drop 
in the average half-live value for hot mice. When this extreme outlier is removed the data 
demonstrates no statistically significant difference between the experimental and control 
groups. The data in the UV/Vis groups have a higher probability o f error due to the
44
complicated protocol and the need for extreme accuracy in each step. This accuracy 
would have been difficult for a newly trained group to obtain. This inexperience means 
the NT data should be considered more accurate for this study. This data suggests that 
there is no difference in the circulation patterns o f nanoparticles based on ambient 
temperature during circulation. This finding suggests that any future study demonstrating 
different pharmacokinetics during accumulation/circulation would be attributed to 
differences in uptake and retention in tumors rather than differences in immune response.
Table 4-2 displays the half-life for each mouse involved in the long vs. short 
study for data collected from both the NanoTracker (NT) and absorbance spectrometry 
(UV/Vis). Both groups demonstrated similar half-lives; a t-test was used to demonstrate 
strength o f the similarity between the two groups. The number o f mice in each group 
suggests that a t-test is not fully applicable in this situation, but it is simply being used to 
demonstrate the strength of the similarity between these two groups. These data suggest 
that there is no difference in the circulation patterns o f nanoparticles based on length of 
injection. This finding suggests that any future study demonstrating different 
pharmacokinetics during accumulation would be attributed to differences in uptake and 
retention in tumors rather than differences in immune response.
4.3.1 Hyperthermia
The hyperthermia experiments demonstrated an average half-life o f 150 and 160 
minutes for cold and hot mice, respectively (shown in Table 4-1).
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Table 4-1: Half-life (in minutes) for cold and hot mice calculated from NanoTracker 
and Blood Draw (UC/Vis) protocols.
NT UV/Vis
Mouse 1 170 115
Mouse 2 98 128
Cold
Mouse 3 180 135
Mouse 4 150 128
Mouse 1 81 9
Mouse 2 99 33
Hot
Mouse 3 201 115
Mouse 4 258 113
When the groups o f mice were compared, the p-values from a T-Test were 0.83 
and 0.08 for NanoTracker, and UV/Vis, respectively. These p-values suggest we are 
unable to reject the null hypothesis of the means being equal, for a=0.05; there is not 
sufficient evidence to prove these groups are dissimilar. These sample sizes do not reflect 
a large enough population for parametric statistics to provide useful insights. Graphs o f 
the blood plasma concentration (representing the concentration o f compartment 1 in a 
one-compartment model) are shown for hot and cold mice (Figure 4-1 and Figure 4-2, 
respectively).
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Figure 4-1: Blood Plasma Concentration vs. Time Hot Mouse 3. This chart is an 
example o f the data charted for the one compartment exponential decay o f a mouse 
kept in a hot environment with NanoTracker and blood draw data.
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Figure 4-2: Blood Plasma Concentration vs. Time Cold Mouse 1. This chart is an 
example o f the data charted for the one compartment exponential decay o f a mouse 
kept at room temperature with NanoTracker and blood draw data.
4.3.2 Long vs. Short
The long vs short experiments did not demonstrated a large change in half-life in 
the long mice, but did in the short mice (shown in Table 4-2).
Table 4-2: Half-life (in minutes) for long and short mice calculated from NanoTracker 
and Blood Draw (UV/Vis) protocols.
NT UV/Vis
Long
Mouse 1 113 119
Mouse 2 106 77
Short
Mouse 1 166 118
Mouse 2 84 142
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When the groups of mice were compared, the p-values from a T-Test were 0.74 
and 0.32 for NanoTracker, and UV/Vis, respectively. These p-values suggest there is no 
significant difference between the means o f the long and short mice, for ot=0.05. These 
sample sizes do not reflect a large enough population for parametric statistics to provide 
useful insights. Graphs o f the blood plasma concentration (representing the concentration 
o f compartment 1 in a one compartment model) are shown for long and short mice 
(Figure 4-3 and Figure 4-4, respectively).
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Figure 4-3: Blood Plasma Concentration vs. Time Long Mouse 1. This chart is an 
example o f the data charted for the one compartment exponential decay o f a long 
injection with NanoTracker and blood draw data.
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Figure 4-4: Blood Plasma Concentration vs. Time Short Mouse 1. This chart is an 
example o f the data charted for the one compartment exponential decay o f a short 
injection with NanoTracker and blood draw data.
4.4 Discussion and Review of Specifications
The data itself does not represent a large enough population to draw significant 
conclusions. A power analysis o f the group suggests a necessary sample size (in each 
group) o f 58 and 10 for Hyperthermia and Long vs. Short, respectively (a=5% P=80%). 
The large number of mice required to demonstrate a significant result for the 
hyperthermia experiment suggested continuing these protocols for a significant result 
would require too many animals and was thus was unrealistic. The continuation o f these 
protocols to a significant result would also not fulfill the primary goal of this study, a
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retrospective review o f protocols. The small number o f completed mice was able to 
provide necessary researcher experience to complete a primary stage retrospective 
protocol review.
The primary goal o f these experiments was a retrospective protocol review. The 
most obvious lesson learned is regarding collecting and saving data, given the need to 
ensure all data meets standards. It is extremely difficult to observe the standard deviations 
o f the two channels and record the piece o f data in the five seconds while the number 
flashes across the screen. It is impossible to calculate the heart rate and ensure that all 
three heart rates are within 20% of the mean for each second, and the AC signal 
amplitude is between three and 100 mV each second. In addition, it was determined the 
data signal deteriorated with time. This problem resulted in two recommendations: ensure 
the mouse is kept warm during the time o f data collection (to encourage adequate 
peripheral blood flow), and discontinuing the practice of collecting NanoTracker data 
under anesthesia. The final major protocol change is related to the confirmation of each 
point using blood draw protocols. The use o f drawing blood from the animal comes into 
question due to the sampling without replacement. This sampling will result in a large 
change o f blood volume o f a mouse. This change in volume has caused other researchers 
to not observe blood plasma concentration during the accumulation phase o f a tumored 
experiment. With the primary goal of future studies to involve the pharmacokinetic 
modeling of the accumulation phase, it was necessary to eliminate the blood draws.
A review o f specifications is presented in Table 4-3, and the data from this set of 
experiments was presented at the “Southern Biomedical Engineering Conference’* in
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Arlington, Texas on April 30, 2011. The abstract from this presentation was published in 
the associated conference proceedings. [81]
Table 4-3: Summary o f observed protocol problems and solutions.
Observed Problem Solution
Inability to meet heart rate and AC 
magnitude data requirements, and 
difficulty observing standard 
deviation
Save data and create rapid review algorithm.
Non-uniform creation of graphs and 
large amount o f anticipated data 
from future saved files
Create MATLAB code to rapidly process 
“good” data and create uniform graphs.
Data quality deterioration.
• Discontinue use o f anesthesia during 
data collection 
• Use space heaters to keep mouse warm
Impractical for use o f blood draws 
related to tumored experiments, in 
addition they create a large human 
“bandwidth” problem for processing.
Discontinue blood draw protocol.
Staining on tail post Au nanoshell 
injection
Slow injection rate to reduce risk of staining 
on tail.
CHAPTER 5
DEVELOPMENT OF AN ENERGY DISPERSIVE 
X-RAY FLUORESCENCE (EDXRF)
TECHNIQUE FOR ELEMENTAL 
ANALYSIS OF GOLD 
NANORODS
5.1 Introduction and Specifications
Throughout the work in the initial experiments of CHAPTER 6: Use o f Real- 
Time Pharmacokinetics to Predict Tumor Uptake o f  Gold Nanorods w e found a need for 
tumor uptake data faster than the traditionally used 1NAA. The old elemental analysis 
methods required batches of tumors to be sent off for analysis taking 4 to 6 weeks. This 
delay was found to be unreasonable for use in preclinical protocol and particle 
development. In addition to the pre-clinical problems, the methods were impossible for 
implementation in clinical settings where the data would be needed in under 12 hours for 
use in clinical decisions. These needs led to these specifications:
• Tissue analysis completed in less than 12 hours
• Minimized skilled tasks to minimize potential error
Our lab group has chosen EDXRF as a system for elemental analysis o f tissue 
samples for several reasons, the main reason being the machine is readily available. This 
quick turn around on samples makes our research go much smoother with a greater level 
o f confidence in our work. We are able to have the amount o f gold in a tumor within 36
52
53
hours of the initial injection o f nanorods into the mouse. This information is very 
important in guiding the next animal experiments.
This device uses x-ray excitation o f a sample to characterize the elemental 
composition. X-rays are used to excite electrons from ground state to create an electron 
hole. This hole is filled by an electron in an outer shell. The energy difference from the 
electron moving from higher to lower energy is released as an x-ray. The released x-rays 
are then measured by an energy-dispersive spectrometer.
The specifications for the development of this elemental analysis protocol are:
• Complete sample analysis 12 hours after collection.
• Minimal sample preparation.
5.2 Materials and Methods
5.2.1 Animal Experiments
All experiments were conducted using BALB/c female mice inoculated with 
CT26.WT tumors on the subcutaneous flank. The accumulation experiment was 
performed on animals with a target tumor size of greater than 5 mm in length and width. 
All animals were handled and cared for in accordance with the Louisiana Tech University 
and Nanospectra Biosciences, Inc. (NBI, Houston, TX) Institutional Animal Care and 
Use Committees.
5.2.2 Temperature Control
Prior to injection and for three and a half hours after injection the animal was kept 
under specific temperature control (35-39°C), to facilitate intravenous cannulation and to 
normalize the extravasation of the gold nanorods. [37]
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5.2.3 Dose Groups
For this experiment, two dose groups were used. Both o f the groups were based 
on the multiples o f standard dose administered by NBI. The first group received 4.5 pL/g 
subject weight o f 100 optical density gold nanorods (Dose group A) and the second group 
received 9 pL/g of 100 optical density gold nanorods (Dose group B).
5.2.4 Anesthesia
For this experiment we used 2,2,2-Tribromoethanol (Sigma-Aldrich T48402) 
mixed with 2-Methyl-2-Butanol (Alfa Aesar A18304), more commonly referred to as 
Avertin, administered via intraperitoneal (IP) injection. The working solution o f Avertin 
was administered at 30 pL of solution per gram body weight. Booster injections (0.5x) 
were delivered as necessary.
5.2.5 Injection
Nanorod injections were administered via intravenous cannulation o f the tail vein, 
using a 28 GA needle. The injections were given at a rate o f 9-18 pL/minute depending 
on dose volume and expected remaining time under anesthesia.
5.2.6 End o f Experiment and Organ Collection
At the end of the experiment, defined as when the blood plasma concentration of 
circulating nanorods reached one optical density, [36] a 20 pL IP injection o f a Ketamine/ 
mix was administered as heavy anesthesia. A dissection was started from the base o f the 
abdominal cavity to sacrifice the animal by exsanguination via cardiac puncture using a 
22 GA needle/syringe prefilled with 100 pL o f heparin. After animal sacrifice, the 
following tissues were collected for further study: heart, lungs, liver, kidneys, spleen, and 
tumor.
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5.2.7 EDXRF Sample Prep
A wet weight o f the tissue was obtained at the time o f extraction. A 20% w/w 
KOH solution was added to the tissue based on the sample weight (3 pL/mg). The tissue 
and base solution were placed in a shaker or rocker until the tissue liquefied, 
approximately four to six hours. Aliquots o f 35 pL (selected to cover our area of 
detection: 15 mm x 12mm, containing approximately 0.04 g o f tumor tissue) were placed 
in EDXRF sample cups on a Prolene® thin film support (Chemplex Industries Inc., 4pm 
thick, Cat. # 3017). The tissue solution was then dried in the sample cup for two hours in 
a vacuum oven at 30° C under 15 in Hg vacuum to reduce the movement o f sample. The 
samples were analyzed in an ARL Quant’X (Thermo Scientific) EDXRF spectrometer (4- 
50 KV x-ray generator, Be window, with 80°geometry between x-ray tube, sample, and 
detector) using a thick Palladium filter (Mid-Zc range) for two minutes (50% dead time). 
Three replicates were prepared from most tissue samples. Each sample cup was scanned 
ten times which produced up to 30 spectra for each tumor. The spinner was turned on 
during each scan to minimize error from the sample placement in the cup.
5.3 Results
The doped tumor samples were plotted and fit with a linear trend line (Eq. 5-1, 
where PPM is the calculated sample concentration in parts per million and PI is peak 
intensity in counts per second per milliamp) for use as a calibration curve (shown in 
Figure 5-1).
PI =  0.0729 * PPM + 0.0174 Eq. 5-1
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This method has a detection limit (3c) o f 1.4 ppm and a sensitivity o f 0.07 
cps/m A/PPM.
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y = 0.073x + 0.0127 
R2 = 0.9838
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Figure 5-1: EDXRF Calibration. This graph demonstrates the raw calibration points 
(□), used calibration curve (dashed line), and a 95% confidence interval (solid line).
5.4 Discussion
The EDXRF protocol for gold in tissue was designed with the following aims: 
quick and easy sample preparation, thin samples, and quantitative results. A 20% K.OH 
solution was chosen, after experimentation, to minimize the time for liquefaction o f the 
tissue. Thin sample geometry was implemented because thick samples were impractical
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given the amount o f tissue available, and to avoid intermediate sample thickness. An 
aliquot o f 35 pL o f tissue was selected to create a thin sample area entirely in the 
detection geometry o f the detector. Quantitative results were obtained using the same 
tissue dilutions and same sample scan time; doped tissue samples for calibration were 
able to provide a linear relationship between counts and tissue concentration.
The calibration curve was used to obtain the values o f concentrations (in ppm) for 
tumor samples (dose group A: n=8, mean = 10.7 PPM, STDEV = ±5.8 PPM, and dose 
group B: n=9, mean = 25.3, STDEV -  ±6.9 PPM). An analysis o f the peak intensity 
(CPS/mA) versus the gold concentration (PPM) using different tissue types showed an R2 
correlation of greater than or equal to 0.93, despite having different slopes (0.0733- 
0.0856 cps/mA/PPM). We hypothesize that the small variations observed in reported 
slopes were attributable to variations in tissue densities given that the regressions were 
similar when multiple preparations o f the same tissue type were analyzed. The calculated 
concentration values for gold in tumors were similar to the work published by Huang and 
colleagues, which used industry standard methods. [30] Commercial laboratories that 
employ 1NAA or 1CP-MS to analyze gold concentration report a detection limit in the 
low PPB range. This EDXRF analysis method demonstrates a detection limit o f 1.4 ppm 
(3o) and a sensitivity of 0.07126 cps/mA/PPM. This higher detection limit is acceptable 
due to the clinical requirements o f rapid results in the PPM range.
The majority o f the problems encountered were due to the presence o f other 
elements that spectrally overlapped with one or more o f the peaks o f interest, as seen in 
previous work. [82] The zinc KPi peak (9.570 Kev) overlaps the Lai peak for gold (9.712 
Kev). Other peaks were explored for potential use; a second peak, the Lp peak ( 11.204-
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11.914 Kev), for gold overlapped the Kai bromine peak (11.906 Kev). The bromine 
peak was attributed to the use of avertin (2-2-2-tribromoethanol) as the anesthesia for this 
experiment. The bromine peak was only observed in tissue samples where avertin was 
used as the anesthesia. For this reason, the use o f anesthesia may influence the elemental 
analysis o f tissues and should be considered among the criteria for selecting anesthesia in 
experimental design.
5.5 Elimination of Zinc Peak
The running hypothesis o f the lid of the machine being the source o f the zinc was 
further evaluated after the publication of the paper. The primary focus o f this evaluation 
was to find a cover for the EDXRF sample cups that is x-ray opaque. Multiple potential 
covers were evaluated: a glass cup (Figure 5-2), a plastic cup (Figure 5-3), a golf ball 
(Figure 5-4), an iron pipe cap (Figure 5-5), and a utility square (Figure 5-6). Due to the 
presence o f zinc peaks, the plastic cup and golf ball were eliminated from potential use. It 
was decided the plastic cup was not x-ray opaque and the golf ball included zinc in the 
core o f the golf ball. Out of the three remaining items (which appeared to be x-ray 
opaque), the utility square was chosen for the ease o f use. It delivered a thin enough layer 
placed on the cup to minimize risk o f movement during machine cycling. The evaluation 
of the spectrum was continued and began with an examination o f the potential 
contaminants o f the Prolene film (the contaminants o f the utility square were known from 
Figure 5-6). Sample spectra were obtained of cups without and with a Prolene film using 
a utility square cover (Figure 5-7 and Figure 5-8, respectively), and no new contaminants 
were found. The next stage involved scanning tissue with no exposure to gold and tissue 
doped with gold (Figure 5-9 and Figure 5-10, respectively). The Spectrum collected for
both o f these samples demonstrated a zinc peak. This finding demonstrates the zinc is an 
endogenous trace element. The search for an x-ray opaque cap was a wasted effort.
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Figure 5-2: EDXRF Spectrum o f  a glass cup. Showing an argon peak.
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Figure 5-3: EDXRF Spectrum o f  a plastic cup. Showing argon and zinc peaks.
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Figure 5-4: EDXRF spectrum o f a golf ball. Showing titanium and zinc peaks.
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Figure 5-5: EDXRF spectrum o f  an iron pipe cap. Showing iron and argon peaks.
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Figure 5-6: EDXRF spectrum o f a utility square. Showing argon, lanthanum,
manganese, and iron peaks.
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Figure 5-7: EDXRF spectrum of an empty EDXRF sample cup with no Prolene film 
capped with the utility square. Showing argon and iron peaks.
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Figure 5-8: EDXRF spectrum of an empty EDXRF sample cup with a Prolene film 
capped with the utility square. Showing argon and iron peaks.
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Figure 5-9: EDXRF spectrum of tumor with no gold exposure on a Prolene film 
capped with the utility square. Showing argon, potassium, iron, and zinc peaks.
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Figure 5-10: EDXRF spectrum of tumor doped to 33 PPM of gold on a Prolene film 
capped with the utility square. Showing argon, potassium, iron, zinc, and gold peaks.
5.6 Review of Specifications
Without this extended effort, the project met the original specifications 
demonstrated in Table 5-1. The data from this project was initially presented at the 2012 
BMES Annual Meeting on October 27, 2012 in a presentation titled “Real-Time 
Measurement o f the Bioavailability Curve o f Experimental Gold Nanorods Towards
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Dose Optimization,’' and is included in a publication titled “Feasibility o f energy 
dispersive x-ray fluorescence determination o f gold in soft tissue for clinical 
applications”. [83]
Table 5-1: Summary o f CHAPTER 5 specifications.
Specification
Complete sample analysis 12 hours 
after collection.
As described in materials and methods, the 
time needed for all steps combined can 
provide analysis in 12 hours.
Minimal sample preparation.
The materials and methods section describes 
the sample preparation. The quick nature of 
the sample preparation (compared to other 
methods) was decided to be faster and 
simpler. In addition, the required skills are 
limited to reproducible pipetting.
CHAPTER 6
USE OF REAL-TIME PHARMACOKINETICS 
TO PREDICT TUMOR UPTAKE 
OF GOLD NANORODS
6.1 Introduction and Specifications
The work in this chapter involves protocol improvements informed by the work in 
CHAPTER 4: Animal Protocol Review Using Gold Nanoshells, and demonstrates the 
need for the Mathematical Modeling work in CHAPTER 3. In addition, the initial 
experiments demonstrated the need for a rapid elemental analysis system developed in 
CHAPTER 5.
Nanoparticle directed photothermal ablation o f tumors relies heavily on the 
accumulation o f nanoparticles in target tissues. An appropriate accumulation o f particles 
is required for proper thermal confinement and ablation o f the target tumor. Preclinical 
studies o f tumor accumulation are being conducted in an effort to more accurately predict 
the accumulation o f nanoparticles. This preclinical study in a murine model works to 
relate the area under the blood plasma concentration curve to uptake and retention in the 
tumor.
Many nanoparticles are currently approved by the FDA or under investigation by 
groups seeking FDA approval, despite the fact that various pharmacokinetic parameters 
that determine the accumulation and retention o f these particles in the target organ are
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mostly unknown. Some o f these particles include Combidex for MRI contrast, and 
NanoTherm Aurimmune, and Auroshell used for cancer therapy. [21] The optimization 
o f treatment variables, such as therapeutic dosage, circulation half-life, and clearance 
rates, is critical in maximizing the efficacy o f a treatment modality. The majority of 
nanorods are removed from the blood by two pathways: opsonization and elimination by 
the RES, and accumulation in tumor tissue due to the EPR. [20], [37], [84], [85] These 
two being the major pathways of removal suggests a correlation between tumor uptake 
and retention and bioavaibility should exist. The purpose o f the tumored studies is to 
correlate standard pharmacokinetic metrics to the uptake and retention of gold nanorods 
in tumors.
This set of experiments is based a hypothesis that pharmacokinetic metrics will be 
a more accurate predictor o f tumor uptake alone and on the following specifications:
• Blood plasma concentrations will be collected in near real-time.
• Discrete blood plasma concentrations will be processed quickly (less than 
5 minutes) after collection for inclusion in an actively changing one- 
compartment pharmacokinetic model.
• Elemental analysis o f tumor tissue is completed in under 12 hours post 
experiment. Additional data processing time is limited to one hour after 
completion o f instrumentation time.
6.2 Materials and Methods
All o f the studies involve animal work conducted under protocol approved by the 
Louisiana Tech University and Nanospectra Biosciences, Inc. Institutional Animal Care
and Use Committee (IACUC). The animals were handled in accordance with the 'Guide 
for the Care and Use of Laboratory Animals’.
All tumored studies involve naive BALB/c females inoculated with 1.5 X 105 (50 
ml injection volume) CT26.WT murine colon carcinoma tumor cells (ATCC) were 
obtained from NBI. When animals arrived at Louisiana Tech University Center for 
Biomedical Engineering and Rehabilitation sciences, the mice were kept in general 
animal housing until the tumors were the proper experimental size, approximately 100 
cubic centimeters.
6.2.1 Initial Experiments
This study involved the use o f eight naive, tumor inoculated BALB/c female 
mice. The mice were divided into two groups: Group A (4.5 pL/g) and Group B (9 pL/g). 
This experiment was designed to explore the differences in circulation half-life and other 
pharmacokinetic parameters between the two dose groups.
6.2.1.1 Temperature Control. Anesthesia, and Injection
The mice were put in a thirty-six degree Celsius environment (Labnet 
International, Inc. Edison, NJ. Model # 21 IDS) for a minimum of forty-five minutes 
prior to injection. The mice were anesthetized using isoflurane anesthesia (given at one 
liter per minute at four percent for induction and two percemt for maintenance), and the 
nanorods were injected over up to ten minute via tail vein at a rate of up to 18 pl/min. 
Once any procedure was completed, the mouse was returned to animal housing, between 
procedures, for the duration o f the accumulation phase.
6.2.1.2 Blood Plasma Concentration Data Collection
Blood plasma concentration data was taken at intervals o f approximately 20 
minutes post injection, 90 minutes post injection, end o f the first half life, 1.33 half-lives,
1.66 half-lives, and at the end of the second half life. These times were based on an 
assumed six-hour half-life, and altered if an extremely long or short half-life was noted.
If it was not possible to collect data at those exact times for any reason the data point was 
taken early or late to get as close to the correct time as possible. The concentration in the 
blood was calculated by using the NanoTracker, and confirmed using an established 
ultraviolet-visible spectroscopy (UV/Vis) protocol (APPENDIX A). The blood for the 
UV/Vis protocol was collected by snipping the end o f the tail and collecting five micro­
liters o f blood using a pipette coated in EDTA, under Isoflurane anesthesia. NanoTracker 
points were taken before and after the blood draw.
6.2.1.3 End o f  experiment
The mouse was sacrificed when the blood plasma concentration reached an 
optical density o f 1±10%. The mouse was sedated using a ketamine and zylazine mixture, 
and then sacrificed by exsanguination via cardiac puncture. Liver, kidneys, spleen, tumor, 
heart, and lungs were collected for EDXRF analysis.
6.2.1.4 Data Analysis
Data analyzed post experiment to create blood plasma concentration curves using 
Microsoft Excel. The Excel spreadsheet was designed to take the raw tabular spectra 
from each blood draw and calculate an adjusted optical density for each time point. From 
this spreadsheet, the data was plotted (optical density versus time).
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6.2.2 Revised Experiments
This experiment involved seventeen tumor inoculated BALB/c female mice. The 
mice were divided into two dose groups (Group A and Group B) to investigate the 
differences in pharmacokinetic metrics, blood plasma concentration and tumor uptake 
based on injected dose.
6.2.2.1 Temperature Control
The mouse was placed in an environment with an ambient temperature o f thirty- 
five degrees Celsius for two and a half hours using a shaking incubator, with the shaker 
off (Labnet International, Inc. Edison, NJ. Model #211DS). For at least one hour prior to 
the injection, the ambient temperature was increased to thirty-nine degrees Celsius.
During injection and while the mice were under anesthesia the temperature was 
controlled using a heating pad (Physitemp Instruments, Inc. Clifton, NJ. Model # TCAT- 
2LV) and/or a space heater for ambient air temperature (Sunbeam Products, Boca Raton, 
FL. Model #SFH 111)
After the injection, the mouse was returned to the incubator kept in a thirty-nine 
degree Celsius environment for the first three and a half hours of the accumulation phase. 
After the first three and a half hours, the mouse was returned to a room temperature 
environment for the remainder of the experiment.
6.2.2.2 Anesthesia and Injection
Intravenous cannulation was established after the mouse was under anesthesia. 
Avertin anesthesia (APPENDIX C) was administered by intraperitoneal injection at the 
dosage o f 25 micro-liters per gram of body weight, while the air flow was maintained
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steady at a rate o f one L/min with the help o f an Oxygen concentrator (Invacare Model: 
IRC5LX02, Elyria, OH) during the experiment.
The nanorod injection was done by cannulating one o f the lateral tail veins. Once 
an intravenous cannula has been established and flushed with saline the NanoTracker was 
attached to the tail. The nanorods were injected at a rate o f up to 18 micro-liters per 
minute using a syringe pump (New Era Pump Systems Inc., Model#NE-1010). The~100 
OD nanorods were intravenously injected at the dosage o f 4.5 pL/gm (Group A) or nine 
pL/gm (Group B) body weight at the rate o f up tol 8 pl/min. The NanoTracker was used 
to monitor the condition o f the mouse while under anesthesia.
6.2.2.3 NanoTracker Data Collection
The NanoTracker was used to read the blood plasma concentration o f nanorods. 
The NanoTracker was attached to the tail o f the mouse in a warm environment, with the 
help of a Physitemp TCAT-2LV controller pad set to 38°C and carefully monitored space 
heaters.
Once temperature stabilization was achieved, the probe was placed on the awake 
animal’s tail and the NanoTracker was allowed to collect data. Five-second averages of 
the values of R were computed to assess signal stability.
Data collection was designed around an assumed six-hour circulation half-life of 
the nanorods, and with approximately five data points in the first half-life, two in the 
second and one in the third half-life. Data should be collected were close to the following 
time points as possible: 5, 45, 120, 240, 360, 450, 720, and 1080 minutes.
6.2.2.4 End o f  Experiment
The mouse was sacrificed when the blood plasma concentration reached an 
optical density o f one plus or minus ten percent. The mouse was sedated using a ketamine 
and zylazine mixture, and then sacrificed by exsanguination via cardiac puncture. Liver, 
kidneys, spleen, tumor, heart, and lungs were collected for EDXRF analysis.
6.2.2.5 Data Analysis
The collected data was be sorted by MATLAB code. A code was specifically written 
to extract the data points that meet all the criteria for data standards. Anticipating 
potential transient problems such as motion artifact or low perfusion, the signal was 
deemed acceptable only if the following criteria were met;
• AC magnitude was in the range o f 10-100 mV peak-to-peak
• the standard deviation o f R was less than 0.03
• The heart rate measured on all three channels (660, 805 and 940 nm) were within 
ten percent o f each other.
The data extracted from the raw experimental data and the average optical density 
value was used to produce a blood plasma concentration curve (using a single decay 
exponential model). This curve was used to calculate the area under the curve (AUC), 
which was used as a pharmacokinetic parameter in the experiment. In addition, the peak 
value and the half-life o f the clearance curve were calculated.
6.2.2.6 EDXRF Tumor Sample Preparation
Using the wet weight o f the tumor, obtained the day o f extraction, 20% (m/m) 
KOH was added at the rate of three pL KOH/mg o f tumor. The tissue was left at room 
temperature, in a low speed shaker until all tissue dissolved in the solution. From each
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tumor sample, 30 pL (of tissue + KOH solution) was pipetted in up to three unique 
EDXRF cups, as many as the mass o f tumor tissue will allow. The solution was then 
dried down in a vacuum oven at 30° C under 15 in Hg vacuum until tissue sample is 
completely dry, this normally takes up to four hours. The dried samples were run in the 
EDXRF machine (Quant’X, Thermo Electron Corporation) and run each sample with ten 
replicates.
The machine calculated a ppm (parts per million) value for the concentration of 
gold in the tumor.
6,2,2,7 EDXRF Tumor Sample Data Analysis
The ppm calculations were manually verified by using the calibration set in the 
machine. The spectra from the calibration set (of known concentration values) were 
extracted and the area under the curve o f the gold L-al peak (9.94 to 9.30 KeV) was 
extracted. From these values, the peak intensities were calculated and a calibration curve 
was established. The calibration curve compared the peak intensity values (cps/mA) 
against known concentration (ppm) values.
6.3 Results
6.3.1 Initial Experiments
The initial experiments demonstrated an average half-life of 276 and 462 minutes 
for group A and B, respectively. Table 6-1 gives the calculated half-life, average, and 
standard deviation for each group.
77
Table 6-1: Half lives for all mice in study (n=8) by dose group with averages.
Group A Group B
Mouse 1 323 452
Mouse 2 251 547
Mouse 3 287 389
Mouse 4 243 460
The results o f this study demonstrate a significant difference between the half- 
lives o f Dose Group A (n=4, mean=276.16 min) and Dose Group B (n=4, mean=461.92 
min) (T-Test: p-value=0.0025, a=0.05).
6.3.2 Revised Experiments
The results of the rapid elemental analysis are displayed on a chart with the 
EDXRF calibration data (Figure 6-1). The tumor concentration ranged from 6.84-41.49 
PPM. Figure 6-2 through Figure 6-9 show scatter plots o f tumor accumulation plotted 
versus pharmacokinetic metrics. Of these, the highest R2 correlations came from Injected 
dose (Figure 6-5, R2=0.458) and Area under the Blood Plasma Concentration Curve 
(Figure 6-2, R2=0.4503). Table 6-2 lists the computed half-lives for all mice in the study, 
and shows the large increase in average half-life from 271 minutes (group A) to 408 
minutes(group B). The p-values from Table 6-3 demonstrate tumor weight is the only 
parameter where we are unable to reject the null hypothesis (the means o f the dose 
groups are equal) (a=0.05).
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Table 6-2: Half lives for all mice in study (n = 17). Dose group A (n = 8) and dose 
group B (n = 9) with averages and standard deviations.
Group A Group B
Mouse 1 320 444
Mouse 2 357 313
Mouse 3 205 523
Mouse 4 267 373
Mouse 5 235 300
Mouse 6 281 356
Mouse 7 268 435
Mouse 8 236 478
Mouse 9 449
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Table 6-3: P-values for comparison o f pharmacokinetic and accumulation 
parameters between dose groups A and B.
p-value
Concentration (PPM) 0.000129721
AUC (OD*min) 0.000120694
AUMC (OD*MIN2) 4.20157E-05
OD Adjusted Dose 6.24664E-07
injected dose (pL) 5.33305E-08
mean residence time 1.87732E-05
Elimination rate constant 0.00044814
half-life (min) 0.000579249
initial concentration from fit (OD) 0.026590645
Tumor Weight (g) 0.703795196
6.4 Discussion and Review of Specifications
The initial experiments elaborated on problems in the protocol, NanoTracker data 
saving problems, found in the experiments discussed in CHAPTER 4: Animal Protocol 
Review. Initial intermediate solutions created from the work discussed in Animal 
Protocol Review CHAPTER 4 were used in the initial experiments. The final solutions 
implemented because of the previous work and this work are discussed in CHAPTER 4.
In addition to the problems with the NanoTracker data extraction, problems and 
delays with the elemental analysis protocols caused the loss of those tissue samples. 
These problems were corrected prior to the beginning o f the revised experiments. The 
elemental analysis technique was more thoroughly established prior to beginning of 
experiments. To correct the problems with the NanoTracker data a more structured 
method o f saving data was established. Through the initial experiments, we also found a 
need for more strict data inclusion rules to be established. In addition the UV/Vis blood
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draws were eliminated from future procedures due to the potential for human error and 
the sampling o f large (by % of total) volumes o f blood without replacement.
6.4.1 Initial Experiments
The half-life data demonstrate an average half-life o f 276 minutes and 462 
minutes for dose groups A and B, respectively. After statistical testing (t-test) we were 
able to reject the null hypothesis (equal means) with a p-value o f 0.0025 (a=0.05).
6.4.2 Revised Experiments
After analysis o f the concentration of gold in the tumors the parameter with the 
highest correlation (R2=0.4605) is a linear correlation with mean residence time. Other 
parameters such as injected dose, area under the blood plasma concentration curve, OD 
adjusted dose, area under the first moment curve, initial concentration, half-life, and 
tumor weight which have R2 values o f 0.458, 0.4503, 0.4321, 0.4084, 0.3578, 0.2477, 
and 0.000007, respectively. These correlations demonstrate the pharmacokinetic 
parameters which best predict tumor accumulation are mean residence time, injected 
dose, and area under the blood plasma concentration curve.
Each o f these parameters demonstrate a significant difference between dose group 
A and dose group B except for tumor weight. This finding is logical because all o f the 
other parameters listed involve differences based on given dose, where the tumor weights 
were controlled to be similar irrespective to dose group.
A review of specifications is presented in Table 6-4, and a subset o f this data was 
presented at the 2012 BMES Annual Meeting on October 27, 2012 in a presentation titled 
“Real-Time Measurement o f the Bioavailability Curve o f Experimental Gold Nanorods 
Towards Dose Optimization,” and is a subset of the data in an in-progress publication
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titled “A Study of Gold Nanorod Bioavailability and Tumor Uptake in a Murine Model.” 
This data was also published in a conference proceedings paper titled “LQR Tracking of 
a Delay Differential Equation Model for the Study o f Nanoparticle Dosing Strategies for 
Cancer Therapy”. [79]
Table 6-4: Review o f specifications.
Specification Status
Blood plasma concentrations will be 
collected in near real-time
Specification met through elimination of 
blood draws and use o f NanoTracker
Discrete blood plasma 
concentrations will be processed 
quickly (less than 5 minutes) after 
collection for inclusion in an actively 
changing one-compartment 
pharmacokinetic model.
Specification met through use o f MATLAB 
code designed to streamline and create 
reproducible data analysis
Elemental analysis o f tumor tissue is 
completed in under 12 hours post 
experiment. Additional data 
processing time is limited to one 
hour after completion of 
instrumentation time.
This specification was met using a rapid 
elemental analysis protocol discussed in 
CHAPTER 5.
CHAPTER 7
OBSERVATION OF COFACTORS ON 
PREDICTION OF TUMOR UPTAKE 
OF GOLD NANOSHELLS
7.1 Introduction and Specifications
An initial analysis using AUC to predict uptake (CHAPTER 6) was unsuccessful 
and had large outliers (R2=0.32, n=8). Recent collaborative modelling efforts examined 
the relationship between extravasation and anatomical and physiological variables. [28] 
The physiological variables evaluated in the model include vessel-wall pore size, 
perfusion, and blood pressure, with flow rate held constant. Based on this modeling 
effort, some o f these parameters have been collected to study in an effort to control or 
improve the predictability o f tumor accumulation. Hyperthermia (38+ deg. C) allows for 
the modulation o f pore size and flow rate in the subdermal ectopic tumor model used.
[76] Particle size or coatings were not modified because of current status in clinical trials. 
Blood pressure was not chemically altered due to a fear o f side effects, but was monitored 
due to a concern that pressure may be modified during the injection phase and early in the 
accumulation phase due to the injected volume or rate o f infusion. [86]
This study was designed to test preliminary protocols to monitor mouse blood 
pressure, core body temperature, and tumor perfusion. The retrospective review of the 
preliminary protocols should include review o f the protocols for feasibility and ability to
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implement the protocol during the experiment, and determine the efficacy o f the current 
protocol.
7.2 Materials and Methods
All o f the studies involve animal work conducted under protocol approved by the 
Louisiana Tech University and Nanospectra Biosciences, Inc. Institutional Animal Care 
and Use Committee (IACUC). The animals were handled in accordance with the 'Guide 
for the Care and Use of Laboratory Animals’.
7.2.1 Investigation o f Cofactors
Nine BALB/c female mice were inoculated with 1.5 X 105 (50 ml injection 
volume) CT26.WT murine colon carcinoma tumor cells (ATCC). Pre-experiment 
ambient temperature protocols were followed: 35°C for two and a half hours followed by 
a minimum of one hour at 39°C immediately prior to injection. Experiment groups were 
divided in two groups a “hot” group to remain at 39°C until the end o f experiment, and a 
“cold” group to return to room temperature (20-25°C) after injection. At a minimum of 
one hour prior to injection thermal images o f the tumor were collected. The mice were 
injected with PEGylated gold nanoshells (four and half pL/g 100 OD). Blood plasma 
concentration observations were collected using the NanoTracker to develop a blood 
plasma concentration curve and develop pharmacokinetic models. Blood pressure and 
rectal temperature was collected at each NanoTracker reading. Elemental analysis o f the 
tumor samples were conducted using a rapid energy dispersive x-ray fluorescence 
technique. [83]
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7.2.2 Intravenous Catheters and Cannulation
Intravenous cannulas ware made using two French Polyurethane Catheter tubing 
(Access Technologies, Skokie, IL Cat. No BC-2P). On one end, used as the needle for 
vascular access, a 28 gauge needle was removed from an insulin syringe (Tyco/ 
Healthcare '/* mL 28G x 'A” insulin syringe REF # 1188528012, VWR Cat. # 84009-742) 
and attached to the tubing. On the other end of the tubing a 27 gauge needle (Becton 
Dickinson 27G x 'A” REF 305109, VWR Cat. # BD305109) was added for slip tip or luer 
lock access to the cannula. Injection solution was loaded in a one-milliliter insulin 
syringe (Becton Dickinson one-milliliter syringe REF 329650, VWR Cat. # BD329654). 
Injection volume and rate were ensured using a syringe pump (New Era Pump Systems, 
Inc. Farmingdale, NY. Model # NE-1010).
7.2.3 Temperature Control
Temperature regulation o f the mice prior to injection was achieved using a 
shaking incubator, with the shaker off (Labnet International, Inc. Edison, NJ. Model #
211DS). During injection and while the mice were under anesthesia the temperature was 
controlled using a heating pad (Physitemp Instruments, Inc. Clifton, NJ. Model # TCAT- 
2LV) and a space heater for ambient air temperature (Sunbeam Products, Boca Raton,
FL. Model #SFH 111).
7.2.4 Gold Nanoshells
PEG modified gold nanoshells (FTS20130919) were obtained from NBI. The 
absorption spectra o f the nanoshells was obtained using a UV/Vis spectrophotometer 
(Beckman Coulter DU 800 Brea, CA.). A one percent dilution o f nanorods was made in
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DI water to obtain the absorbance at 600, 805, and 940 nm. These values are required as 
input values o f the NanoTracker to ensure proper calculations.
7.2.5 Blood Plasma Concentration Observations
Blood plasma concentration was observed at intervals o f approximately: 5, 45,
120, 240, 360, 450, and 720 minutes post injection. These times were based on an 
assumed six-hour half-life, and altered if an extremely long or short half-life was noted.
If it was not possible to collect data at those exact times for any reason the data point was 
taken early or late to get as close to the correct time as possible.
Blood plasma concentration was collected using the NanoTracker. Data was 
saved in a raw data directory with the name of the file corresponding to the minutes after 
injection when data save started. The only metric able to me monitored quickly as the 
data was passing on the screen was the standard deviation o f the two ratios. An effort was 
made to collect ten “good” data points to ensure 30 seconds of good data (30 seconds is 
equal to six -  five second data points). The required six points was given an extra four 
points in case some o f the other data metrics were not met and some had to be eliminated. 
All save files were processed by MATLAB code, and if irregularities were found the data 
was collected again.
7.2.6 One-Compartment Pharmacokinetic Model
Each saved data file (per observation) was processed through MATLAB 
(APPENDIX B: Sample MATLAB processing code). The MATLAB code was able to 
provide filtering for noise and unreliable data points. In addition, the MATLAB code 
created data files and exported charts. The files and charts included metrics o f standard
one-compartment pharmacokinetic models including: exponential trend line, r2, half-life, 
area under the curve, area under the first moment curve, and mean residence time.
7.2.7 End o f Experiment and Animal Termination
The end of experiment was determined to be when the blood plasma 
concentration reached one optical density plus or minus ten percent. The animal was 
sacrificed by exsanguination via cardiac puncture, under heavy anesthesia (an 
intraperitoneal injection o f a ketamine (100mg/ml)/zylazine (lOOmg/ml) mixture at 0.1 
ml/lOg o f body weight). The tumor was collected for elemental analysis; the liver, spleen 
kidneys, heart, and lungs were collected for potential elemental analysis. [83]
7,3 Results
The tumor accumulation for hot mice ranged from 9-12.6 PPM and the cold mice 
were 21.9 and 12.4 PPM (shown in Table 7-1).
Table 7-2 elaborated further on standard pharmacokinetic metrics used for 
evaluation o f each injection. The core body temperature and systolic blood pressure 
measurements did not demonstrate a significant difference between (p-values o f 0.14 and 
0.065, respectively) the two different test groups. The data is demonstrated in tukey plots 
for core body temperature (Figure 7-1) and systolic blood pressure (Figure 7-2). The 
NanoTracker data was used to construct all and average data graphs for hot (Figure 7-3 
and Figure 7-4) and cold mice (Figure 7-5 and Figure 7-6). These figures demonstrate the 
NanoTracker data processed in the form o f a rapidly produced one compartment 
pharmacokinetic model.
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Table 7-1: Tumor Accumulation by Mouse. Average tumor accumulation is 13.1 ± 5.2 
PPM.
Mouse Number Experimental Group Tumor Accumulation (PPM)
2013121OA-4 Hot 9.0
20131210B-0 Hot 9.3
2013121 OB-1 Hot 12.6
20131210A-2 Cold 21.9
20131210A-5 Cold 12.4
Table 7-2: Pharmacokinetic Metrics by Mouse. AUC- Area Under the blood plasma 
concentration Curve, SBP- maximum observed Systolic Blood Pressure, DBP- 
maximum observed Diastolic Blood Pressure, Tern- maximum oberved core body 
Temperature, MRT- Mean Residence Time, T 1/2 - circulation half-life, a- model 
predicted initial concentration, a- model predicted elimination rate constant, r2- model 
correlation coefficient.
Mouse Number 
& Group AUC SBP DBP Temp MRT T1 /2 a a r2
A-l Hot 131.8 133 69 35.7 56.1 368 1.25 -0.002 0.88
A-4 Hot 244.3 132 106 38.7 79.9 183 1.8 -0.004 0.65
B-0 Hot 985.3 144 117 38 250.5 414 2.58 -0.002 0.92
B-l Hot 271.1 111 62 38.6 110.3 362 1.41 -0.002 0.53
B-2 Hot 567.3 129 96 38.2 167.9 425 2 -0.002 0.98
A-2 Cold 447.0 118 82 38.8 131.6 266 2.1 -0.003 0.95
A-3 Cold 391.3 160 87 38.1 125.1 217 1.99 -0.003 0.97
A-5 Cold 586.0 117 87 38.7 160.9 241 2.46 -0.003 0.86
B-3 Cold 781.5 149 91 32.8 167.7 248 3.19 -0.003 0.89
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Figure 7-1: Tukey boxplot, with outliers (o). Individual temperature observations are 
shown (X). The average core temperature was 36.46 ± 1.26 °C and 37.04± 1.56 °C for 
hot and cold mice, respectively. A student’s t-test demonstrated a p-value o f 0.140 
(a=0.05).
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Figure 7-2: Tukey boxplot, with outliers (o). Individual systolic blood pressure 
observations are shown (X). The average systolic blood pressure was 115 ± 16 mmHg 
and 106 ± 18 mmHg for hot and cold mice, respectively. A student’s t-test 
demonstrated a p-value o f 0.065 (a=0.05).
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Figure 7-3: All Data Chart for Mouse 2013 121 OB-1: This chart contains every 
NanoTracker point collected for Mouse 20131210B-1, a member o f the hot mouse 
group.
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Figure 7-4: Average Data Chart for Mouse 2013 12 1 OB-1: This chart contains an 
averaged blood plasma concentration for each representative time point collected for 
Mouse 20131210B-1, a member o f the hot mouse group. The chart also includes 
values for the exponential fit, half-life, AUC, AUMC, and MRT.
Figure 7-5: All Data Chart for Mouse 20131210A-5: This chart contains every 
NanoTracker point collected for Mouse 20131210A-5, a member o f  the cold mouse 
group.
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Figure 7-6: Average Data Chart for Mouse 2013121OA-5: This chart contains an 
averaged blood plasma concentration for each representative time point collected for 
Mouse 20131210A-5, a member o f the cold mouse group. The chart also includes 
values for the exponential fit, half-life, AUC, AUMC, and MRT
The hyperthermia protocol was determined to have no effect on the core body 
temperature of the animal. The average core body temperature of the “hot” group was 
lower than the average temperature o f the “cold” mice. The student’s t-test comparing the 
hot and cold groups revealed a p-value o f 0.140. Based on the p-value, we are unable to 
reject the null hypothesis; the means are not dissimilar. This finding shows that we are 
not changing the core body temperature using the current ambient temperature protocol. 
The thermal imaging perfusion protocol was indeterminate, and is currently being 
redesigned using new instrumentation (Laser Doppler Flowmetry). Future studies (using
7.4 Discussion and Review of Specifications
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Laser Doppler Flowmetry) will have to evaluate the use o f this hyperthermia protocol to 
effect tumor perfusion. The average accumulation values o f 13.05 ± 5.23 PPM for the 
five mice in this data set, and 11.31 ±5.16 PPM for the eight mice in the 1 x data set from 
zero are very similar. These data sets also produce a p-value o f 0.574 when compared 
using a student’s t-test. The cofactors data set of five mice is too small for parametric 
testing to provide meaningful results, but these values suggest the two data sets are not 
dissimilar. This comparison suggests the hyperthermia protocol may not be affecting 
tumor perfusion. The monitoring o f blood pressure was determined to be unnecessary.
The blood pressure data did not support a difference (based on student’s t-test) between 
the systolic blood pressure o f the two groups. In addition, the average systolic blood 
pressure reading is 110.46 ± 17.22 mmHg. No mouse trended to have higher systolic 
blood pressures, mice saw transient spikes in blood pressure where high or low values 
were never seen for more than one point in a row. I was unable to find any trending with 
time our mouse to describe the behavior o f systolic blood pressure. The lack o f definitive 
trends, and the timing difficulty o f collecting blood pressure data at each blood plasma 
concentration reading lead to recommendations to reduce the number o f blood pressure 
readings. The blood pressure readings should be taken at the beginning o f the experiment 
or on multiple days before the experiment to exclude mice with chronic hypertension.
A summary o f protocol problems and solutions is presented in Table 7-3, and a 
subset of this data was presented (presentation title: “The Use o f Real-Time Optical 
Feedback to Improve Outcomes”) at Photonics West BiOS on February 2, 2014, with an 
associated conference proceedings publication. [86]
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Table 7-3: Summary o f observed protocol problems and solutions.
Observed Problem Solution
Blood pressure measurements take 
too long and create delays in data 
collection
Take fewer blood pressure measurements 
during accumulation phase.
Ambient temperature protocols do 
not change the core body 
temperature of the mouse
Discontinue use o f protocols and consider 
chemically induced systemic hyperthermia
Thermal imaging did not show 
useable correlations
Consider new instrumentation: Laser Doppler 
Flowmetry
Blood pressure measurements did 
not show trends between mice or 
groups
Suggests lower need for monitoring during 
accumulation phase.
CHAPTER 8
RETICULOENDOTHELIAL SYSTEM  
BLOCKADE AND REDOSING 
OF GOLD NANORODS 
IN A MURINE 
MODEL
8.1 Introduction and Hypothesis
Several types o f nanomaterials are under investigation in preclinical and clinical 
trials for use in cancer therapies. Current medical-grade particles are constructed from a 
variety of materials including lipids, polymers, and metals, [21] and are routinely 
delivered intravenously for passive or active accumulation in tumor tissue. [20] 
Accumulation via the vascular route increases as the nanoparticle circulation time 
increases and the nanoparticle circulation time increases by discouraging their removal 
by the reticuloendothelial system (RES). The high removal rate observed by the RES of 
charged and hydrophobic particles, [27] which is a requirement o f a stable colloidal 
system, creates a need to mask the charge by adding a surface coating for nanoparticle 
therapies to be most effective.
A common surface coating for stealth nanoparticles is polyethylene glycol (PEG) 
which uses steric hindrance to provide for colloidal stability and to prevent the adsorption 
o f opsonins. [27] PEG, in a liposome formulation, provides a significantly longer half-life 
compared to an unshielded type, but some groups show this advantage may diminish in
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subsequent injections. [46], [47] Some studies point to PEG as a source o f the accelerated 
blood clearance (ABC) phenomenon and found that PEG acts as a type-two T cell- 
independent antigen. [48], [50] Ichihara and colleagues suggest that the mechanism 
responsible for ABC could be anti-PEG IgM [50]; this theory is corroborated by studies 
which identified a soluble serum factor as a mediator from serum transfusion studies.
[46], [47]
The Kupffer cells in the liver provide a major removal route o f nanoparticles by 
the RES. Multiple agents have been evaluated to suppress the actions o f the Kupffer cells. 
Particles cleared by the RES which can utilize this adjuvant therapy include types of 
liposomes, [87] iron oxide nanoparticles, [88] gold nanoshells, [89] gold nanorods, [90] 
quantum dots, [91] dendrimers, [92] micelles, [93] and carbon nanotubes. [90] Souhami 
and colleagues used dextran sulfate or carbon as a blockade agent and demonstrated 
limited success and utility at decreasing clearance. [94] Van Rooijen and colleagues 
compared the efficacy o f liposome-encapsulated clodronate, propamidine, and 
ethylenediaminetetraacetic acid. [95] The results o f their study demonstrated propamidine 
was the most effective followed by clodronate. [95]
In contrast to the toxic nature of other available RES blockade agents, X- 
Carrageenan demonstrated utility in suppression o f hepatic phagocytosis and was 
designated as Generally Recognized as Safe (GRAS) by the FDA.[96] This GRAS 
designation means that companies might not be required to complete extensive and costly 
studies on X-Carrageenan to prove safety. X-Carrageenan could be used with particles 
currently under investigation as an adjuvant therapy; developers would not have to restart
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the trials o f their particles due to changes with the surface modification, saving time and 
money.
This study evaluates RES blockade using X-carrageenan intravenously 
administered immediately prior to the injection of PEGylated gold nanorods (NRs). The 
quantifiable extension of their circulation time was measured using the NanoTracker.
[23], [36] The real-time observations were used to create the population pharmacokinetic 
(PK) model and calculate PK metrics, thus pointing to the potential clinical utility of the 
optical sensing method.
This study is hypothesis driven work. The hypothesis o f this experiment is the use 
of an adjuvant RES blockade agent will be able to increase the circulation half-life of 
PEGylated gold nanorods.
8.2 Materials and Methods
8.2.1 Overview
All animals were handled and cared for in accordance with the Louisiana 
Tech University Institutional Animal Care and Use Committee. Ten BALB/c female mice 
were initially assigned one of three groups (A, B, or C). In subsequent weeks, some mice 
were moved between groups B and C and then, after week 3, mice in groups B and C 
were combined to form group D, as shown in Figure 8-1: Flow chart describing the flow 
of protocols.. NRs were prepared by Nanospectra Biosciences, Inc. (NBI, Houston, TX) 
using the methods described by Goodrich and colleagues. [37] Post-manufacturing 
characterization was performed at NBI prior to shipment (shown in Table 8-1); the 
extinction spectrum of the gold nanoparticles was measured using a UV-Vis 
spectrophotometer prior to the injection to quantify concentration and stability.
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Intravenous injections and blood plasma concentrations were monitored using the 
NanoTracker, and a population pharmacokinetic (PK) model was created from that data.
Group A1
" t
Group A3
 i .....
Group A7
Figure 8-1: Flow chart describing the flow o f protocols. 
Table 8-1: Post-Manufacturing Characterization.
Approximate Size (TEM) 8 x 24 nm
Absorbance at Peak 91.7 OD (5), 762 nm
Absorbance at 800 nm 81.1 OD
Surface Zeta Potential -11.2mV
CTAB Concentration 60 pM
8,2,2 Injection
Prior to injection, the animals were kept in an incubator set at 37°C for a 
minimum of 30 minutes to facilitate intravenous cannulation. Isoflurane inhalation 
anesthesia was used to immobilize the animal for injection and to assist with the
Group B1
i \
 *    .
Group B2 £
Group 83
Group C 1
! ..........
t
Group C2
 V . ....
Group 0 3
Group D1
 i .....
Group D5
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collection of the first OD reading. NR (NB1 Batch TR20110221) injections were 
administered via intravenous cannulation o f the tail vein. The majority of injections were 
delivered at a rate o f 20 pL/minute by syringe but nine (of 35) injections were made at 40 
pL/minute. Optical density data was collected using the NanoTracker. Data was then 
processed in MATLAB to provide data for pharmacokinetic analysis.
8.2.3 Dose of k-Carrageenan
A dose of 25 mg/kg body weight was reported [97] to produce sufficient 
depression of RES functions. The dose was increased to 50 mg/kg to increase the 
likelihood o f a statistically valid result in a small sample group, k-carrageenan (Sigma 
22049-5G-F, CAS 9064-57-7) was added to mammalian normal saline to create a stock 
solution of 8 mg/mL (chosen due to solubility o f A-carrageenan in saline) and the volume 
o f the stock solution injected was 6.25 pL/g o f A.-carrageenan.
8.2.4 Experimental and Control groups
Group A mice were given a standard dose of X-carrageenan (50 mg/kg) 
immediately prior to a standard injection o f gold NRs (4.5 pL/g of 100 OD NRs). Group 
B mice received a pre-injection of normal saline equal in volume to that of a standard X- 
carrageenan dose immediately prior to a standard NR injection. Group C mice received a 
standard NR injection. Mice could switch between groups B and C on a weekly basis, as 
needed. Group D mice received a standard injection of ^ .-carrageenan immediately prior 
to a standard NR injection; Group D mice were originally participants in groups B and/or 
C. Toxicity was not studied during these experiments; however, all animals survived at 
least 60 days after their last involvement in this study at which point they were assigned 
to other experimental protocols.
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8.2.5 Data collection
Blood plasma concentration in OD was collected using the MWPPG[23], [36] at 
intervals o f approximately: 5, 45, 120, 240, 360, 450, and 720 minutes post injection (see 
Yendluri 2014 for full blood plasma concentration curves). [98] These times were based 
on an assumed six-hour half-life, and altered if an extremely long or short half-life was 
noted. If it was not possible to collect data at those exact times for any reason the data 
point was taken early or late to get as close to the correct time as possible.
8.2.6 Population Pharmacokinetics
The real-time blood plasma concentration observations were used to create a 
population PK model to quantify the effect o f X-carrageenan on the circulation o f gold 
NRs. The injected dose was changed from units o f pL injected volume to pg o f injected 
gold by multiplying the injected volume by a factor o f 2.79 pg/pL for a 100 OD solution. 
The blood plasma concentration data was changed from units o f OD to units o f pg/pL by 
multiplying blood plasma concentration in OD by 0.0279 pg/pL per 1 -OD solution, as 
provided by NB1.
The PK model was fit to blood plasma concentration data in a Bayesian manner 
using the WinBUGS 1.4.3 [99] software called from R using the R2WinBUGS package. 
[100] Five chains were used for each analysis with each chain having a burn-in period o f 
10,000 iterations, a post bum-in period o f 10,000 iterations, and every fifth sample was 
retained. This method results in a total sample o f 10,000 iterations. Gelman-Rubin 
diagnostics were used to confirm convergence o f the PK model.
The covariate free PK model compartment structure and variability models were 
selected by comparing the deviance information criterion o f PK models. The following
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model components were evaluated: one- and two-compartment structures; absorption; 
inter-mouse variability and inter-trial variability on PK variables (e.g. clearance and 
volume o f distribution); and additive, proportional, and combined residual error models. 
Non-informative normal distributions were used as the prior distributions for PK model 
parameters. Inverse gamma distributions were used for the precision o f normally 
distributed errors.
After selection of the base model, covariate effects o f pharmacokinetic model 
parameters were tested using a backwards elimination technique. The effects o f (1) 
receiving /.-carrageenan (yes/no) on clearance and/or volume o f distribution, (2) 
receiving a pre-injection bolus (yes/no) on clearance and/or volume o f distribution, (3) 
number o f previous injections on clearance (Groups B & C only), and (4) an additive 
model o f weight on clearance and volume o f distribution were tested. Covariate effects 
whose 95% credible intervals (CrI) did cross zero were eliminated one-at-a-time until all 
remaining covariate effects were significant.
The final PK model was used to calculate the circulation half-life and area under 
the blood plasma concentration versus time curve (AUC) for each mouse trial. A t-test 
was used to compare the half-life and AUC for mice who received a pre-injection o f X- 
carrageenan (Groups A &D) with mice that did not (Groups B & C). A P-value less than
0.05 was considered statistically significant.
8.3 Results
A one-compartment model with intravenous injection, inter-trial variability on 
clearance and volume of distribution, and a proportional error model best fit the data.
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Two significant covariates were identified: the effect o f pre-injection o f carrageenan on 
clearance rate and pre-injection bolus on volume, shown in Table 8-2.
Table 8-2: Population pharamcokinetic parameters for all trials (n=35).
Pharmacokinetic
Parameter
(95% Credible Interval)
Clearance
... Population Median, No.Carrageenan (Groups: B &C) 18.9(15.9-22.6) pL/min
... Population Median, Carrageenan (Groups: A & D) 11.2 (8.8- 13.9) pL/min
... Inter-Trial Variability 5.1 (3.4 - 7.8) pL/min
Volume o f Distribution
... Population Median, No Bolus (Group: C) 3,189 (2,392 - 3,906) pL
... Population Median, Bolus (Groups: A, B, & D) 4,180 (3,784 - 4,587) pL
... Inter-Trial Variability 1,041 (772-1,420) pL
Residual Variability 14.9% (13.7-16.3% )
X-Carrageenan decreases the median clearance rate from 18.9 (15.9 - 22.6) 
pL/min to 11.2 (8.8 -13.9) pL/min, Table 8-2. This decrease results in extending the 
mean half-life from 160 ± 22 minutes (Groups B & C) to 264 ± 73 minutes (Groups A 
&D), p<0.01, and raising the AUC of PEGylated gold NRs from 506 ± 142 OD*min 
(Groups B & C) to 893 ± 324 OD*min (Groups A & D), p<0.01 demonstrated in Figure 
8-2. These findings support the previously reported use o f  ^ .-carrageenan as a transient 
RES blockade agent, and extend the circulation o f PEGylated gold NRs. Table 8-3 shows 
the average half-life and AUC values for each sub-group o f mice in the experiment.
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Figure 8-2: Tukey boxplot, with individual trials shown (X). Carrageenan- Groups A 
& D, No.Carrageenan- Groups B & C.
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Table 8-3: Half-life and AUC for each group.
Bolus Type Group ti/2 (mins) mean ± stdev
AUC (OD*min) 
mean ± stdev n
l-C
A1 358 ±53 1,301 ±255 5
A3 219 ± 47 595 ±232 4
A7 173 ± 11 570 ±53 2
Saline
B1 140 ± 19 435± 103 3
B2 167 ±20 469 ± 93 3
B3 161 ± 7 414 ±80 3
None
Cl 190 ± 31 773 ± 17 2
C2 145 ± 11 487 ± 9 2
C3 161 ±26 558± 193 2
l-C
D1 245 ± 42 891 ± 166 4
D5 257 ± 47 855± 143 5
The pre-injection bolus is associated with a significant increase in the volume of 
distribution. In the trials without a pre-injection bolus the median volume o f distribution 
was 3,198 (95% Crl, 2,392 -  3,906) pL, and in mice with a pre-injection the median 
volume o f distribution was 4,180 (95% Crl, 3,784 - 4,587) pL.
Some additional observations between groups are note-worthy although the small 
sample size o f sub-groups prohibits rigorous statistical analysis. The initial injection 
following ^.-carrageenan pre-injection (A 1) appeared to demonstrate a higher AUC value 
(1,301 OD*min) than the subsequent injections (A3= 595, A7=570 OD*min). This 
observation seems to support a 4-week redosing cycle similar to PEGylated liposomes as 
reported by Dams and colleagues. [47] When /.-carrageenan is given to mice with 
previous NRs exposure, but not previous /,-carrageenan exposure, the AUC increased to 
near baseline levels (from B2/B3/C2/C3= 474±102 OD*min to D l= 891±166 OD*min), 
shown in Figure 8-3. In addition, while the PK model did not show a significant redosing 
effect in groups B & C, there was a trend toward an increase in clearance with redosing
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Figure 8-3: Tukey boxplot, with outliers (o). Individual subjects are shown (X). 
These groups demonstrate the ability of X-carrageenan to raise the AUC after multiple 
exposures to PEGylated gold NRs.
8.4 Discussion
The findings o f this study demonstrate the utility of ^ .-carrageenan in increasing 
the circulation half-life and AUC of PEGylated gold NRs. In addition, the use o f X-
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carrageenan after a series of NR injections was able to increase AUC values to be similar 
to the AUC of naive injections. These findings are noteworthy for investigators who wish 
to achieve the longer circulation times without particle modification, or who wish to use a 
series o f nanoparticle injections.
One finding of note is the significant change in volume o f distribution with a pre­
injection bolus. This finding is important because o f the positive correlation of half-life 
with volume o f distribution; this correlation means an increase in volume o f distribution 
will increase the half-life. A potential for increase in half-life caused by an increase in 
volume o f distribution should be considered during experimental design; investigators 
should be mindful o f pre-injection and injection volumes. Both volumes should be 
minimized to avoid unnecessary increase in circulation half-life, especially in small 
animals where small injection volumes are non-negligible relative to the volume of 
distribution.
A previous study demonstrated an approximated 15% decrease in blood 
clearance, which suggests a limited utility of RES blockade. [94] However, the current 
study demonstrates a 59.3% decrease in clearance using a different blockade agent (k- 
carrageenan) and using metal nanoparticles in place of liposomes. This demonstrates that 
RES blockade is a viable mechanism for prolonging the circulation o f nanoparticles.
The study design demonstrates the ability to observe changes in volume of 
distribution based on pre-injection bolus by creating an appropriate number and style of 
control groups. One limitation of this study is the small sample size in each group. These 
sample sizes were selected to demonstrate feasibility of X,-carrageenan with the minimal 
number o f animals, and limits the ability to analyze secondary effects such as those noted
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as “observations”. These observations will require additional testing to confirm the 
results reported here. In addition, the dosage and dosing strategy will also require further 
experimentation to optimize. A 50 mg/kg dose o f X-carrageenan was used in this study 
but the effects on RES blockade and redosing of different /.-carrageenan doses is 
unknown. No deleterious effects were observed from the use o f X-carrageenan, and all 
mice survived though 60 days post study when they were assigned to new protocols.
Although the injection rate was double the intended rate (40 pL/min vs. 20 
pL/min) for 9 of the 35 injections, because the pharmacokinetic model accounts for the 
rate o f the injection, these deviations are accounted for the pharmacokinetic analysis and 
do not affect these results. Also, because the time required for all injections (2.5 or 5 
minutes) is relatively short compared to the half-life o f the NRs (-200 minutes), the 
effect on the actual OD measurements is minimal.
The same amount of NRs were delivered for all trials and both injection rates are 
reasonable for mice so physiological differences in the mice (e.g., blowout) at the higher 
injection rate were neither expected nor observed.
RES blockade, using an agent such as ^.-carrageenan, will cause a significant 
increase in the circulation time and exposure o f gold nanorods, which could augment 
therapeutic efficacy. Future work might seek to establish use and safety guidelines for 
the intravenous use of k-carrageenan or identify other viable non-toxic agents for 
blockade.
This data was presented (presentation title: “The Use o f Real-Time Optical 
Feedback to Improve Outcomes”) at Photonics West BiOS on February 2, 2014, with an 
associated conference proceedings publication, [86] and is the data set for an in-progress
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publication titled “Suppression o f the Reticuloendothelial System Using k-Carrageenan 
to Prolong the Circulation o f Gold Nanoparticles”
8.4.1 Summary
1. X-carrageenan is generally recognized as safe by the FDA
2. X-carrageenan increases the circulation time and AUC of PEGylated gold 
nanorods, at a higher rate than predicted by previous studies.
3. Increased AUC and circulation time after previous exposure to PEGylated 
nanoparticles suggests utility to prophylactically minimize ABC.
4. This adjuvant therapy could assist with increasing circulation time and exposure 
o f particles without disrupting experimental trials already underway.
5. Pre-Injection boluses and large injections can increase volume o f distribution and 
therefore increase circulation half-life.
RES blockade should be effective for all nanoparticles cleared by the RES.
CHAPTER 9
INJECTION NORMALIZATION
9.1 Introduction and Specifications
One noticeable difference in each injection o f  nanoshells and nanorods in the 
large disparity o f the initial concentration noticed after injection (noticeable in the data 
from
Table 7-2 and Table 8-3, and the graphs in CHAPTER 6 and APPENDIX E). One 
theory regarding the large disparity in half-lives and clearance involves the observed 
differences in maximum blood plasma concentration. The specification o f this work is to 
achieve a reproducible maximum blood plasma concentration ± 0.05 OD.
9.2 Methods
The desire to fix this disparity for future testing o f importance led to this body o f 
work to create a more reproducible injection. Three methods have been considered and 
tested: equal volumes, 70/30, and rate modified. The equal volumes involved injections 
o f the same volume regardless o f the weight o f the mouse (this would completely ignore 
the inter-mouse variability on volume o f distribution). The 70/30 method would use basic 
volume calculations using Eq. 9-1 (where Cx is the concentration o f solution one and two, 
and Vx is the volume of solution one and two) to calculate an injection volume and inject
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70% o f that volume. Following a blood plasma concentration reading, the remaining 
“30%” was injected to appropriately hit a blood plasma concentration target (dose is not 
conserved).
CiVi =  C2 V2 Eq.9-1
A sister “Stair Step” protocol where “ l/8x” injections were given until close to the target 
blood plasma concentration when smaller injections could be given at the discretion of 
the researcher. The final method was designed to inject nanoshells or nanorods until the 
desired blood plasma concentration was observed (dose is not conserved). The rate is 
adjusted between ten and 20 pL/min at the discretion o f the researcher to ensure the 
target ±0.05 OD is met.
All o f the studies involve animal work conducted under protocol approved by the 
Louisiana Tech University Institutional Animal Care and Use Committee (IACUC). The 
animals were handled in accordance with the ‘Guide for the Care and Use o f Laboratory 
Animals’.
9.2.1 Intravenous Catheters and Cannulation
Intravenous cannulas ware made using two French Polyurethane Catheter tubing 
(Access Technologies, Skokie, IL Cat. No BC-2P). On one end, used as the needle for 
vascular access, a 28-gauge needle was removed from an insulin syringe (Tyco/ 
Healthcare 'A mL 28G x VS” insulin syringe REF # 1188528012, VWR Cat. # 84009-742) 
and attached to the tubing. On the other end o f the tubing a 27 gauge needle (Becton 
Dickinson 27G x VS” REF 305109, VWR Cat. # BD305109) was added for slip tip or luer 
lock access to the cannula. Injection solution was loaded in a one mL insulin syringe 
(Becton Dickinson 1 mL syringe REF 329650, VWR Cat. # BD329654). Injection
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volume and rate were ensured using a syringe pump (New Era Pump Systems, Inc. 
Farmingdale, NY. Model # NE-1010).
9.2.2 Temperature Control
Temperature regulation o f the mice prior to injection was achieved using a 
shaking incubator, with the shaker off (Labnet International, Inc. Edison, NJ. Model #
211DS). During injection and while the mice were under anesthesia the temperature was 
controlled using a heating pad (Physitemp Instruments, Inc. Clifton, NJ. Model # TCAT- 
2LV) and a space heater for ambient air temperature (Sunbeam Products, Boca Raton,
FL. Model #SFH 111).
9.2.2.1 Blood Plasma Concentration Observations
Blood plasma concentration was collected using the NanoTracker. Data was 
saved in a raw data directory named “injection”. The file was imported to Microsoft 
Excel for manual filtering to exclude data that does not meet data standards. Graphs o f 
the injections curves were then plotted in Microsoft Excel.
9.2.3 One-Compartment Pharmacokinetic Model
Each saved data file (per observation) was processed through MATLAB 
(APPENDIX B: Sample MATLAB processing code). The MATLAB code was able to 
provide filtering for noise and unreliable data points. In addition, the MATLAB code 
created data files and exported charts. The files and charts included metrics o f standard 
one-compartment pharmacokinetic models including: exponential trend line, r2, half-life, 
area under the curve, area under the first moment curve, and mean residence time.
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9.3 Results
9.3.1 Equal Volumes
The approximate maximum blood plasma concentration for the equal volumes 
was demonstrated to range from two and one tenth to three and one tenth OD, 
demonstrated in Table 9-1. Figure 9-1 through Figure 9-7 are the injection profile for 
each injection given under this protocol.
Table 9-1: Maximum blood plasma concentrations for equal volumes experiments.
Figure Approximate Max Blood Plasma (OD)
Figure 9-1 2.8
Figure 9-2 2.6
Figure 9-3 2.4
Figure 9-4 2.4
Figure 9-5 2.1
Figure 9-6 3.1
Figure 9-7 2.7
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Figure 9-1: Blood Plasma Concentration Curve Mouse A Equal Volumes Injection 1.
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Figure 9-2: Blood Plasma Concentration Curve Mouse A Equal Volumes Injection 2.
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Figure 9-3: Blood Plasma Concentration Curve Mouse B Equal Volumes Injection 1.
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Figure 9-4: Blood Plasma Concentration Curve Mouse B Equal Volumes Injection 2.
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Figure 9-5: Blood Plasma Concentration Curve Mouse 20140728B-0 Equal Volumes
Injection.
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Figure 9-6: Blood Plasma Concentration Curve Mouse 20140728B-2 Equal Volumes 
Injection.
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Figure 9-7: Blood Plasma Concentration Curve Mouse 20140728B-3 Equal Volumes
Injection.
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9.3.2 Step Injections
Table 9-2 shows a sample worksheet for the how calculations were made in the 
70/30 step injection with the observed injection profile shown in Figure 9-8. The 
injection profile of the l/8x stair step injection is shown in Figure 9-9.
Table 9-2: Mouse 20140728B-1 Stair Step Worksheet.
Mouse # 20140728B-1 70% Volume Target 76.384
Date 2014-11-1821:38 70% OD Target 3.85
Mouse Weight 24.8 70% OD Observed 3
Mouse Blood Volume 1984 % Observed 77.92%
Target OD 5.5
Solution OD 100 30% Volume Target 32.736
Target Injection 109.12 Adjusted Volume 42.0112
6
0 ------------------------------------------------------------------------------------------
20 25 30 35 40
Time (Mins)
•  Injection — 70 Step — ——30 Step
Figure 9-8: Blood Plasma Concentration Curve for Mouse 20140728B-1 70/30 Stair 
Step. With each observed data point (•), the 70% target (solid line), and the 30% 
target (dashed line).
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Figure 9-9: Blood Plasma Concentration Curve for Mouse 20140728B-1 l/8x dose 
Stair Step.
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9.3.3 Continuous Infusion
The final protocol, deemed successful, is demonstrated through two successful 
injections profiles (Figure 9-10 and Figure 9-11).
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Figure 9-10: Injection phase blood plasma concentration curve for Mouse 20140804- 
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Figure 9-11: Injection phase blood plasma concentration curve for Mouse 20140804- 
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9.4 Discussion and Review of Specifications
9.4.1 Equal Volumes
The equal volumes method was not expected to be meet specifications, but 
potentially narrow the spread of maximum blood plasma concentrations. It was based on 
the idea that we were injecting different volumes in different mice and observing 
different maximum concentrations; we should trying injecting the same volume to 
observe the outcome. Table 9-1 shows the spread o f the data from this group, ranging 
from 2.1-3.1 OD. This range o f data did not meet specifications and the next method was 
attempted.
9.4.2 Step Injections
The 70/30 stair step shown in Figure 9-8 was created using a convoluted protocol 
that was not able to attain the level o f precision desired. As demonstrated by the target 
being five and a half OD and the observed maximum blood plasmas concentration being 
closer to three and a half. The convoluted nature o f the injection scheme was filled with 
problems, such as a difficult to follow protocol regarding the volume o f the 30 % step. 
This particular mistake was made during the injection and caused the final target blood 
plasma concentration to drop from 5.5-4.65 OD by not attempting to make up for the 
previously lost concentration in the 70% step. The problems found in the protocol, and 
ease o f mistakes (even by the person who created the protocol) lead to create a more 
simple “stair step” injection pattern (shown in Figure 9-9). This injection method was 
successful (and met specifications) in reaching the target blood plasma concentration of
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four OD. The idea of discrete injections was abandoned for the creation o f the more 
simple continuous infusion targeted injections.
9.4.3 Continuous Infusion
The continuous infusion method is successful for targeting o f maximum blood 
plasma concentration. The initial plan where injection rate was 20 pL/min for the first 
80% of the injection and then slowed to ten microliters per minute caused the noise or 
discontinuity seen around ten minutes in Figure 9-10 and Figure 9-11. Due to these 
discontinuities, it is recommended to pick one injection rate (the current recommendation 
is 15 pL/min) and use it throughout the entire injection. Table 9-3 outlines the summary 
o f specifications and which methods were effective.
Table 9-3: Summary of Specifications.
Specification Status
Achieve a reproducible maximum 
blood plasma concentration ± 0.05 
OD
Met by both the "Stair Step" and the 
‘‘Continuous Infusion” method. With the 
Recommendation: use the “Continuous 
Infusion" method with a set flow rate o f  15 
pL/min.
CHAPTER 10
PROTOCOL UPDATES
The experiments discussed throughout this dissertation developed a set of 
recommendations on providing more reproducible experiments in a murine model. Each 
chapter discusses some o f the lessons learned and how these lessons were turned into 
specifications for future experiments. This chapter outlines some o f the more important 
protocol recommendations that are omnipresent in the experimentation of the O ’Neal 
group.
10.1 Injection
The setup o f the catheter system for pre-clinical use can create a loss o f fluid that 
is a large given the scale o f a mouse injection. When using the injection pump system to 
give a specified volume to the mouse it is suggested to minimize the number o f times a 
syringe is changed out. Each time a syringe is changed out some fluid is lost by dripping 
out from around the blunt tip connection to the catheter. In a human injection, the loss of 
a few microliters from drips during syringe change would be negligible, but with the 
small volumes injected for a mouse, it is proportionately large. For this reason the revised 
recommendation for injection is to estimate the volume of saline in the tubing prior to 
animal catheterization, and add that “dead” volume o f saline to the volume o f intended 
injection and set the syringe pump to the new total volume (injection volume combined
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with “dead” volume). When the syringe pump has moved the combined volume into the 
animal this should minimize the loss of nanoparticles and provide a more reproducible 
injection. In addition, the use o f the same length o f catheter tubing (six inches) and 
needles with the same gauge and length should improve the precision o f nanoparticle 
delivery.
10.2 NanoTracker
10.2.1 Animal Heating
Animals with poor peripheral circulation are difficult to get NanoTracker signals 
from, due to the location o f the probe on the tail. The use o f a deltaphase isothermal pad 
or physitemp feedback heating pad is recommended. In addition to the heating pad, the 
use o f space heaters to ensure the airflow around the mouse is 35-39°C will assist in 
providing peripheral circulation for an adequate signal.
10.2.2 Data Collection and Analysis
To ensure the reproducible analysis o f NanoTracker data a series o f MATLAB 
codes have been developed. These MATLAB codes ensure the basic data standards are 
met (including: the heart rates from each channel should be ±20% of the computed mean,
the AC amplitude should be greater than three millivolts and less than 100 millivolts, and
the standard deviation o f the optical density readings o f the averaged time should be less 
than 0.03). A sample MATLAB code is shown in APPENDIX B: Sample MATLAB 
processing code. This code does the following:
• imports the raw data from a saved file
• evaluates each line for the data standards (above)
• ensures the entire time period (default o f five seconds) is considered good 
data
• removes the unnecessary lines of data (the four duplicate lines o f the five 
second time period)
• creates a new array with only the filtered data
• graphs the data (both averaged for a time point and each good data point)
• provides the following (on the graph o f time point averaged data)
o an exponential regression 
o area under the curve (by trapezoidal rule) 
o area under the first moment curve 
o the mean residence time 
o half-life (based off the exponential regression)
• Saves the data files as excel spreadsheets
• Exports the graphs as JPEG and MATLAB figure files
• Can create a “WinBUGS import file”
10.3 Hatteras Blood Pressure System
The Hatteras blood pressure system should be started approximately 30 minutes 
before the intended use to ensure the animal platform has ample time to warm up. This 
need for the platform to be warm means the settings must be entered not just the machine 
being switched on. The balloon should be replaced a minimum of once a week, and 
pressure tested each day. The high (150 mmHg) and low (50 mmHg) pressure calibration 
should be performed a minimum of every three days. The mouse tail should be held in
place manually or by restraint system during measurement. The mouse is unlikely to 
remain motionless for the amount o f time needed and will require immobilization o f the 
tail. A set o f typical system parameters is given in Table 10-1.
Table 10-1: Summary Hatteras Blood Pressure System Settings.
Parameter Recommended Value
Preliminary Cycles 3
Measurement Cycles 8
Movement Detection On
Minimum Pulse Amplitude 6
Number o f Peaks 40
Minimum peaks 0.5
Maximum pressure 200
Pulse timeout 30 seconds
Measurement 60 seconds
Time between measurements 2.5 seconds
Systolic threshold 20
Signal below threshold 90
Time below 0.5
Diastolic threshold 80
Signal below 90
Time below 0.5
Temperature 100-110
CHAPTER 11 
CONCLUSIONS AND FUTURE WORK
A series of protocol updates and recommendations have been presented. These 
recommendations are made based on meeting specifications outlined in Table 1-1. The 
specifications were developed from observed real-world problems in the original pre- 
clinical and clinical methods, some o f which are still in use today. These protocols have 
been implemented in pre-clinical studies and are driving our work toward a set of "‘best’7 
practices for nanomedicine. This body o f work demonstrates the beginning o f a long road 
of improvements to pre-clinical protocols. Our industrial partner (Nanospectra 
Biosciences, Inc.) currently conducting pre-clinical and clinical studies has not adopted 
the protocol improvements made in this dissertation. Closing the gap between the 
developed pre-clinical practices (in an academic setting) and pre-clinical and clinical 
setting (in industry) is part of future work that is necessary for a set of best practices to 
fully develop. The primary goal of these recommendations is improved clinical 
outcomes. The primary work toward improved clinical outcomes is developing through:
• Making treatment decisions through observation o f clinical signs (real­
time blood plasma concentration and rapid elemental analysis o f biopsied 
tissue
• Quantifying influential factors, and continuing to search for new factors
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• Improved particle characterization (ensuring the solution is what you think 
you are injecting through UV/vis and/or DLS)
• Ensuring the proper dose is found circulating through real-time blood 
plasma concentration readings
• Acknowledging problems with the animal model and de-prioritizing 
model specific problems (i.e. stop solving problems with no clinical 
relevance, and focus on problems that can improve clinical outcomes)
• Realize not all problems have been found yet and we need to continually 
reevaluate for new methods o f improving clinical outcomes.
In advance o f the implementation o f industry standard popPK modeling 
techniques, the NanoTracker and current MATLAB coding were able to create 
individualized pk models. These individual one-compartment pk models are designed for 
near-real-time clinical implementation. The personalized one-compartment models 
provide the ability for comparison o f physiological responses to the treatment and allow 
us to head toward personalized cancer treatments. The popPK models can assist NBI with 
their ongoing pre-clinical and clinical trials, and provide useful starting point information 
tailored to the patient (provided from the popPK models).
The protocols associated with the use o f the NanoTracker have been evaluated, 
and modified as needed for use with PEGylated gold nanoshells and nanorods. The 
protocol updates implemented in this work emphasize the ability to record data for post 
processing that is more sophisticated. This sophistication includes the ability to 
reproducibly enforce data quality standards and create graphs, currently with MATLAB. 
The importance of standardized data analysis and monitoring is found primarily when
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future protocols use these devices to inform clinical decisions in real time. Early 
academic or pre-clinical studies have the luxury o f time for making decisions, but clinical 
decisions will be made using this information in an urgent and life threatening climate. 
The climate these decisions will be made in highlights the need for standardized and 
easily interpreted results. The path toward data driven medicine will involve the 
personalized one compartment modeling from real-time blood plasma monitoring, and 
ability to observe tumor uptake metrics. The ability to collect tumor uptake data is 
available through rapid elemental analysis.
The proposed rapid elemental analysis technique (EDXRF- used in this work) 
allows for the quantitative analysis o f gold in animal tissues. With a focus on future 
clinical implementation, elemental analysis will be required to be completed in under 12 
hours. The current 12-hour window is based on timing o f currently implemented clinical 
treatment protocols. This elemental analysis technique meets these requirements, and 
continues to be used in our animal research due to its ease o f use and short turnaround 
time. Additional quantitative studies would be required to fully validate the technique and 
characterize the sources of errors in the protocol prior to human clinical use.
Future work should build on the set o f one-compartment models to create a 
desired blood plasma concentration curve. From the desired curve there is potential for 
the implementation of traditional electrical engineering controls methods [79] to attempt 
to ensure a uniform blood plasma concentration curve. In future clinical settings, it will 
be possible for the delivery o f nanoparticles to be different and contain new dosing 
strategies to ensure optimization of tumor uptake. The limitations o f our current murine 
model only allow for one injection over a short period (limited by the time an animal is
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capable o f safely being under anesthesia), but clinical work can be conducted with longer 
infusions (because human infusions can be given with larger variation). In addition to the 
ability to create a more uniform blood plasma concentration curve from patient to patient, 
the one-compartment models will be able to assist with the detection o f undesired 
reactions (e.g. anaphylaxis). The use of popPK models could be used to explore 
individual variables from previous experiments for significant cofactors, and potentially 
explore minor protocol differences between research groups using particles provided by 
Nanospectra Biosciences, Inc. As future studies search for improving clinical outcomes, 
it is important to remember the ideas, protocol updates, and specifications listed here are 
a starting point. Some factors of clinical importance may not have been discovered yet.
APPENDIX A
MOUSE BLOOD DRAW PROTOCOL
A .l Theory
Blood draws taken from a mouse post injection o f nanoshells can be used to 
measure the concentration o f circulating nanoshells. UV-Vis spectra o f the diluted blood 
draws can be analyzed using Beer’s Law to separate extinction caused by the 
oxyhemoglobin and nanoshells in the sample. This is done by observing the value at the 
peak extinction wavelength for nanoshells and by using Eq. A -l:
Apeak =  ( £ N S ^ N S  +  e H b 0 2 ^ H b 0 2 ) ^ -  Eq. A-l
Where A is the extinction at the peak wavelength, the e ’s are the extinction 
coefficients for the two compounds o f interest (oxyhemoglobin(compound b) and 
nanoshells(compound a) in this case) at the peak wavelength, and cns and cnb02 are the 
concentrations nanoshells and Hb02. Note that we are using the extinction coefficient 
for oxyhemoglobin because the blood samples have been exposed to air in the sampling 
process. Therefore, we assume that the hemoglobin is fully oxygenated. Also note that 
the extinction is pathlength dependent, but we assume that D is one centimeter.
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The concentration o f nanoshells in the sample can be expressed using Eq. A-2
n  _  A p e a k ~ ^ H b 0 2 £ H b 0 2  
l NS  —  •
£NS c  aEq. A-2
A .1.1 Finding the Extinction Coefficients for Nanoshells
Since Beer’s Law expresses concentrations as moles/liter, we will examine the 
nanoshells as if each one was one atom. Therefore, you will notice that the molarities of 
nanoshells that are found in each sample are extremely low, but since they are such good 
extinguishers of light, their molar extinction coefficients will be extremely high. As 
reported, batches of nanoshells are manufactured to have a peak optical density o f 100 at 
a wavelength between 760 and 820 nm. We will use an optical density o f 100 for 760 
nm. The molar extinction coefficient is found using Eq. A-3:
A ns
£ n s  —
Cns Eq. A-3
The concentration of the nanoshells is reported as a number of particles/ml. We 
can find a molarity from Eq. A-4:
NPis  lO O O m i  m o l  m o l e s  NPis  _  . . * -------- * ------------------   . Ed. A-4
m l  11 6 . 0 2 - 1 0 2 3  NPis L ^
A. 1.2 Blood Draws and Measurements
Once the extinction coefficient used in Eq. A-l & Eq. A-2 is found, we can inject 
nanoparticles into a mouse, take blood samples, and examine them. The procedure for 
taking a blood sample and analyzing it is as follows:
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1. Fill a micro-cuvette with 95 pi o f 10% Triton-X 100. Blank the spectrometer 
using that micro-cuvette.
2. Heparinize a ten microliter pipette tip by sucking in five microliter of heparin and 
then releasing it leaving a layer of heparin inside the tip
3. Obtain a five microliter blood sample using the heparinized tip and mix this with 
the Triton-X in the cuvette
4. Scan this cuvette using the previously specified wavelengths (500-11 OOnm) and 
record the extinction at 805 nm (Let’s say that is (igo5 )
5. Dilute the sample using 100 pi Triton-X and scan again and record the extinction 
at 560 nm (p560)
6. The formula for optical density is as follows, in Eq. A-5:
0*805 "  ( ^ )  * 2 * 840) * 20 = OD. Eq. A-5
A.2 Adjustments
There will be an error in volume. To adjust for that multiply the final OD value by
1 .9 5
MS60
A.3 Calibration Curve/Typical Results
The spectra from blood draws taken from a mouse injected with nanoparticles can 
be seen in Figure A -l, and the calibration curve is shown in Figure A-2.
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Figure A -l: Extinction spectra o f blood prior to (raw blood) and post (all other 
spectra) injection. Note how the extinction at 760 nm increases greatly in comparison 
to 940 nm and then begins to return to a spectrum more like that for raw blood.
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APPENDIX B
SAMPLE MATLAB PROCESSING CODE
The code below is an example o f the MATLAB processing code used to process 
NanoTracker data. The purpose o f this particular code is to extract the data from the RES 
Blockade experiments, process and create basic blood plasma concentration graphs, and 
create the input files for WinBUGS.
clear all 
clc
close all
mousenumber=input('enter mouse number as YYYYMMDD(CAGE)-(M01JSE): 
lnjectionVolumel=input('enter the volume of 100 OD NS or NR '); 
InjectionVolume=lnjectionVolumel-75;
Mouse Weight=input('enter the weight of the mouse '); 
group=input(’enter the group number ','s');
Dose=(InjectionVolume)/(4.5*MouseWeight);
InjectionVolumeSTR=num2str(InjectionVolume);
MouseWeightSTR=num2str(MouseWeight);
DoseSTR=num2str(Dose);
nonmem(l,:)={'#ID','TIMH’,'AMT','R ATE YDV',’MDV','DOSE','WT'};
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nonmem(2,:)={'(D' ’()' Injection VolumeSTR 'O’ 7 T  DoseSTR MouseWeightSTR}; 
alldata=zeros(l,24);
numberofdp=input('enter the number o f data points;'); 
countdp=l;
while countdp <=numberofdp
clear rawdatafile; clear raw data; clear timeresolveddata; 
clear prelimiiltereddata; clear filtereddata 
%PULL DATA FILE & TIME RESOLVE
filestarttime=input('Enter start time of file '.s');
rawdatafile=['C:\Users\ibmag_000\Documents\Dropbox\NCTSG Lab\Ravv 
Data\C’arragcenan Eperiments\WinBUGSV,mousenumber,’V,filestarttime];
filestarttime=str2double(filestarttime);
rawdata=load(rawdatafile);
initialtime=rawdata( 1,10);
ti mereso I veddata=rawdata;
timeresolveddata(:, 10)=rawdata(:, 10)-initialtime+filestarttime;
count=I;
count2=l;
length=size(rawdata); 
length l=length( 1,1);
while count <= lengthl %the purpose of this while loop is to remove rows with bad data
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%CHECK HR SI 1)1 V 
clear X;
X=[timeresolveddata(count, 1) timeresolveddata(count,2) timeresolveddata(count,3)];
average=mean(X);
averageminus=average*0.8;
averageplus=average* 1.2;
if timeresolveddata(count, 1) <= averageplus 
includeHR=l; 
else 
includeHR=0; 
end
if timeresolveddata(count,2) <= averageplus 
includeHRl=l; 
else 
ineludeHRI=0; 
end
if timeresolveddata(count,3) <= averageplus 
includeHR2=l; 
else
includeHR2=0;
end
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if averageminus <= timeresolveddata(count,l) 
includeHR3=l; 
else
includeHR3=0;
end
if averageminus <= timeresolveddata(count,2) 
includeHR4=l; 
else 
includeHR4=0; 
end
if averageminus <= timeresolveddata(count,3) 
includeHR5=l; 
else
includeHR5=0;
end
%( HlX'k AC AMPLITUDE 
if timeresolveddata(count,7) <=0.10 
includeAC=l; 
else
includeAC=0;
end
if timeresolveddata(count,8) <=0.10
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includeAC 1=1; 
else
includeAC 1=0; 
end
if timeresolveddata(count,9) <=0.10 
includeAC2=l; 
else
includeAC2=0;
end
if 0.003 <= timeresolveddata(count,7) 
includeAC3=l; 
else
includeAC3=0;
end
if 0.003 <= timeresolveddata(count,8) 
includeAC4=l; 
else
includeAC4=0;
end
if 0.003 <= timeresolveddata(count,9) 
includeAC5=l; 
else
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includeAC5=0;
end
% C I  I l i C K  S I D I . V  
if timeresolveddata(count,13) <= 0.03 
includeSTDEV=l;
else
includeSTDEV=0;
end
if timeresolveddata(count,16) <= 0.03 
includeSTDEVl=l; 
else
includeSTDEVl=0;
end
INCLUDE=includeHR*includeHRl*includeHR2*includeHR3*includeHR4*includeHR5
*includeSTDEV*includeSTDEVl*includeAC*includeACl*includeAC2*includeAC3*in
cludeAC4*includeAC5;
if INCLUDE == 1 
prelimfiltereddata(count2,:)=timeresolveddata(count,:); 
count2=count2+l; 
else 
end
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count=count+l; 
end
%REMOVE DUPLICATE LINES
count=3;
count 1 = 1;
length2=size(prelimfiltereddata);
Iength3=length2( 1,1 )-2;
while count <= length3 % rem o v e  duplica te  values 
‘.’.'.EXTRACT BY STDEV I
if prelimfi!tereddata(count, 13)== prelimfiltereddata(count+2,13);
includeplustwol=l;
else
includeplustwo I =0; 
end
if prelimfiltereddata(count, 13)== prelimfiltereddata(count-2,13);
inc ludem inustwo 1=1; 
else
includeminustwol=0;
end
INCLUDE 1 =includeplustwo 1 *includeminustwo 1;
146
if INCLUDE 1 ~=0 
fi ltereddata(count 1,: )=prel imfi ltereddata(count,:); 
count l=count 1+1; 
else 
end
eount=count+l; 
end
numberofgooddatapoints=size(fiItereddata);
averagedata(countdp, 1 )=mean(filtereddata(:, 10)); %time 
averagedata(countdp,3)=mean(filtereddata(:, 18)); %optical density
averagedata(countdp,2)=numberofgooddatapoints(l,l); %nuinber of points being 
averaged
alldata=[alldata;filtereddata];
TimeSTR=num2str(averagedata(countdp, 1)); 
OD_STR=num2str(averagedata(countdp,3));
nonmem(countdp+2,:)={'!□' TimeSTR '()’ 'O' OD STR 'O' DoseSTR MouseWeightSTR};
countdp=countdp+1; 
clear T imeSTR
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clear OD SIR 
end
%Kxponential Regression 
mdl=@(a,x)(a( 1 )*exp(-a(2)*x)); 
a0=[7;0.004];
beta=n I i n fi t( averagedata(:, 1 ),averagedata(:,3),mdl,a0);
xrange=0:0.01:1030;
uganda=mdl(beta,xrange);
averagedata(:,4)=mdl(beta,averagedata(:, 1));
r=corr2(averagedata(:,3),averagedata(:,4));
rsquarred=rA2;
halflife=log(.5)/-beta(2,1);
°i)Calculate ALJC 
datal= [0 0 averagedata(l,3) 0]; 
data2=[datal ;averagedata]; 
data2(:,5)=data2(:, 1 ).!(!data2(:,3);
AUC=trapz(data2(:, 1 ),data2(:,3)); 
AUMC=trapz(data2(:, 1 ),data2(:,5)); 
MRT=AUMC/AUC;
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AUCs=num2str(AUC);
AUMCs=num2str(AUMC);
MRTs=num2str(MRT);
figl=figure(l);
MM=num2str(filtereddata( 1,20));
DD=num2str(filtereddata( 1,21));
YYYY=num2str(filtereddata( 1,19)); 
doe=[MM,'/',DD,7',YYYY];
plot(averagedata(:,l),averagedata(:,3),'b.',xrange,Uganda,'"-.') 
titlestr=['CARRAGEHNAN Mouse ’,mousenumber,’ Date o f Experiment: \doe]; 
title(titlestr);
betaA=num2str(beta( 1,1)); 
betaB=num2str(beta(2,1)); 
halflifestr=num2str(halflife); 
rsquarred2=num2str(rsquarred);
annotationstr{ 1 }=['y=',betaA,'*exp(-’,betaB,'*t) rA2=',rsquarred2,’ Half 
L i f e-,halflifestr,'m i as’];
annotationstr{2}=['AUC=',AUCs,'OD*inin. AUMC=',AUMCs,'0D*niinA2 
M RT=',MRT s,'m i n s'];
text(25,0.5,annotationstr)
legend('data','curve fit')
xlabel('Time (mins)');
ylabel('Concentration (Optical Density)');
149
axis([0 400 0 4.5]);
fig2=figure(2);
plot(alldata([2:end],10),alldata([2:end],18),'b.')
titlestr=['CARRAGEENAN Mouse ',mousenumber,' Date of Experiment: ’,doe];
title(titlestr);
xIabel('Time (mins)');
ylabel('Coneentration (Optical Density)');
axis([0 400 0 4.5]);
savestr=['C:U sers ibmag 000 Documents Dropbox NCTSG
Lab\Carrageenan\Data\WinBUGS\Group ’,group,"‘.Group’,group,'Mouse',mousenumber];
%...........Save Average Data Sheet and Figures
saveas(fig 1 ,[savestr,'averagedata']); 
saveas(fig 1 ,[savestr,'averagedata.jpg']);
header={’Time','Number of PointsVAverage OD',’Curve Fit OD at time'}; 
xlswrite([savestr,'averagedata'],header,'sheet I'); 
xlswrite([savestr,'averagedata'],averagedata,'sheet l','A2’);
%........... Save All Data Sheet and Figures
alldataheader={'UR I ','HR2','I IR3','DC 1 ','DC 2','DC3','AC I ','AC2','AC3','TlMf ','R 1 ','A V
(i R 1 ','STDBV R 1 ','R2','A VG R2',’STDFV
R2’,'SP02','OD’,'YEAR','MONFH','DAY','HOUR','MIN','SBC'};
saveas(fig2,[savestr,'alldata']);
saveas(fig2,[savestr,'al ldata.jpg']);
xlswrite([savestr,'alldata'],alldata,'sheet 1 ','A I');
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xlswrite([savestr,’alldata’],alldataheader,'sheet I ','A 1'); 
%—.......Save nonmem
xlswrite([savestr,'nonmem'],nonmem,’sheet 1 ’,'A 1 ’); 
beep
APPENDIX C
2,2,2-TRIBROMOETHANOL (AVERTIN)
Avertin is useful for use in procedures where immobilization is less than 20 
minutes and with no significant pain or distress. Avertin should provide good skeletal 
muscle relaxation and a moderate degree of respiratory depression.
C .l Contraindication
Repeated administrations o f  avertin are contraindicated.
Do NOT inject intravenous, animal death would be expected within minutes.
C.2 Materials
2,2,2-tribromoethanol (Sigma-Aldrich T48402)
2-Methyl-2-Butanol (Alfa Aesar A18304)
C.3 Avertin Stock Solution
Mix:
1. 15 g 2,2,2-tribromoethanol
2. 15.5 mL 2-Methyl-2-Butanol
3. Mix overnight in dark (amber) bottle at room temperature, (be sure to use clean 
stir bar)
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The stock solution has a shelf life o f six months when stored wrapped in foil in a 
dark cabinet at room temperature. The following information MUST be on the outside of 
the bottle and the box the bottle is stored in: Solution, Expiration date, grams of 2,2,2- 
tribromoethanol and lot number, mL 2-Methyl-2-Butanol and lot number.
C.4 Avertin Working Solution
Mix:
1. 0.1 mL Avertin Stock Solution
2. 7.9 mL 0.9% Sterile Saline
3. Mix in a dark bottle and store overnight
4. Filter sterilize with 0.22 pm filter, label and store at four to six degrees Celsius.
Working solution has a shelf life o f six months if unopened.
Once the working solution has been opened it has a shelf life o f one week.
All containers of working solution must be labeled with the following 
information: Solution, Expiration date (once opened), Date o f sterilization, Your Initials, 
mL Avertin stock solution, mL saline.
C.5 Animal Injection
Avertin is given via intraperitoneal (IP) injection o f Avertin Working Solution at 
the following dose:
Normal injection for slow particle infusion: 25 pL/g body weight.
Normal injection for standard immobilization: 20 pL/g body weight.
APPENDIX D
USE OF REAL-TIME PHARMACOKINETICS 
TO PREDICT TUMOR UPTAKE
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Figure D -l: Charts for mouse 20111104A-5 (Group A- 21.08PPM). Top: All Data, 
Bottom: Averaged Data.
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Figure D-2: Charts for mouse 20111104B-1 (Group A- 12.83 PPM). Top: All Data,
Bottom: Averaged Data.
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Bottom: Averaged Data.
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Figure D-5: Charts for mouse 20111202B-3 (Group A- 9.46 PPM). Top: All Data,
Bottom: Averaged Data.
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Figure D-6: Charts for mouse 20120120D-0 (Group A- 6.89 PPM). Top: All Data,
Bottom: Averaged Data.
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Figure D-7: Charts for mouse 20120220A-3-5 (Group A- 16.69 PPM). Top: All Data,
Bottom: Averaged Data.
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Figure D-8: Charts for mouse 20120220A-5 (Group A- 7.36 PPM). Top: All Data,
Bottom: Averaged Data.
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Figure D-9: Charts for mouse 20111104A-1 (Group B-23.59 PPM). Top: All Data,
Bottom: Averaged Data.
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Figure D-10: Charts for mouse 20111104A-3 (Group B- 38.35 PPM). Top: All Data,
Bottom: Averaged Data.
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Figure D -ll:  Charts for mouse 20111202A-0 (Group B- 23.24 PPM). Top: All Data,
Bottom: Averaged Data.
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Figure D-12: Charts for mouse 20111202A-1 (Group B- 21.64 PPM). Top: All Data,
Bottom: Averaged Data.
165
S.
I  ■
3 ft
5
I * -  ;S ; I
M9ui»20in^02A*:>(QOiip 2«> 0*leo’ 12/20^2011
700 4'Xi rioc- go<:
tone .rnnsi
1000 170C
Moult* ?rn 1 ?ro?A {Grnup ?x< Omtm of trtprnrmmit IVKOSttT.
y-4.S0M*e*K-O 0CCi282*?i r*-C.$1163
HWf ufe»2*7 ?212 mn%. AU01&S3 6fc*4GDV*n
> 200 400 660
Tiipfl inwsl
Figure D-13: Charts for mouse 20111202A-2 (Group B- 30.03 PPM). Top: All Data,
Bottom: Averaged Data.
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Figure D-14: Charts for mouse 20111202B-1 (Group B- 24.82 PPM). Top: All Data,
Bottom: Averaged Data.
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Figure D-15: Charts for mouse 20120120A-0 (Group B- 17.43 PPM). Top: All Data,
Bottom: Averaged Data.
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Figure D-16: Charts for mouse 20120120C-3 (Group B- 23.30 PPM). Top: All Data,
Bottom: Averaged Data.
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Figure D-17: Charts for mouse 20120120C-5 (Group B- 23.95 PPM). Top: All Data,
Bottom: Averaged Data.
APPENDIX E
CONTINUATION OF DATA FOR CHAPTER 7: 
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Figure E-2: Charts for mouse 20131210A-2 (cold mouse). Top: All Data, Bottom
Averaged Data.
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Figure E-5: Charts for mouse 2013121OA-5 (cold mouse). Top: All Data, Bottom:
Averaged Data.
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APPENDIX F
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE 
APPROVAL LETTER
IN ST IT U T IO N A L  A N IM A L  CARE A N D  U S E  C O M M ITTEE
L ouisiana Tech U niversity
25 October 2011
Dr. Patrick O ’Neal, Ph.D.
Biomedical Engineering 
Louisiana Tech University 
Campus Box # 58
Dear Dr. O ’Neal:
The Louisiana Tech University’s Institutional Animal Care and Use Committee (IACUC) met o n  
17 October and approved your amended protocol entitled:
Vanopartiele Tracking For Cancer Therapy
The committee members feel that the transport of mice from Houston that have been inoculated 
with cancer cells is appropriate, and in keeping with your previous protocols. Please make sure 
that the animals are in a transport box with adequate water and that the vehicle be air-conditioned 
at all times so that the animals will not become dehydrated or overheated.
You and the students have been approved for a limit of 50 animals in this initial study beginning 
1 November 2011. Please remember that you are required to keep adequate and accurate records 
of all procedures, results, and the number of animals used in this protocol. You are required to 
provide a progress report each year by 1 October. If the project should need to be extended 
beyond 31 October 2014, the third year, you will be required to submit a new protocol. Any 
changes you need to make in the protocol before the termination date must be submitted to the 
IACUC on the amendment form for approval before implementation.
Keep for your research records and results for three years after termination of the project. These 
records must be available for review by the IACUC or state and federal ammat use agencies.
Each year by 31 October you will be required to complete a summary of number o f animals used 
in this protocol used for the United States Agricultural Agency (USDA). Note that failure to 
follow this protocol as approved may result in the termination of research. If you have any 
questions please call me at 318-243-07% or via e-mail at igspauld'qilatech.edu.
Sincerely.
James G. Spaulding, Chair 
Louisiana Tech University IACUC
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